The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Table of Contents

CELEBRATING 70 YEARS  
SPOTLIGHTING OUR IMPACT  
ADVANCING OUR MISSION IN 2019  
TAKING ON CHILDREN’S CANCER FROM EVERY DIRECTION  
ACCELERATING CURES  
DRIVING CLINICAL TRIAL INNOVATION, EDUCATION AND ENROLLMENT  
HELPING PATIENTS THROUGHOUT THEIR CANCER EXPERIENCE  
BREAKING DOWN BARRIERS TO CARE  
DRIVING SUPPORT ACROSS THE COUNTRY  
PARTNERING FOR PROGRESS TOWARD CURES  
RECOGNIZING OUR SUPPORTERS  
ACKNOWLEDGING OUR EXTRAORDINARY VOLUNTEERS  
FINANCIALS  
ACKNOWLEDGMENTS
Dear Friends,

You are part of our story—the story of The Leukemia & Lymphoma Society (LLS)—which begins with one family’s hope and will end with curing cancer in our lifetime.

Rudolph and Antoinette Roesler de Villiers founded LLS in 1949 after losing their 16-year-old son Robbie to leukemia. Determined to spare other families the devastating loss of a child, the de Villiers set out to transform cancer treatment and care. As an organization founded by a family for families, our vision is rooted firmly in the de Villiers’ relentless drive to create a world without blood cancer.

Since our founding, generations of patients, survivors, caregivers, families, volunteers, researchers, healthcare professionals and supporters have joined our quest for cancer cures. In 2019, LLS celebrated our 70th anniversary by looking to inspiration of the past to propel us forward. To mark the occasion, we invited our global community to help us grow a digital family tree on www.LLS.org by sharing stories of impact.

Stories like that of Dr. James Holland, who was a trailblazing researcher. In 1955, LLS awarded a grant to Dr. Holland, whose discovery helped establish the first standard of care for children with leukemia. Today, this story resonates even more in light of our recent launch of The LLS Children’s Initiative, a $100 million comprehensive endeavor to deliver cures and better care to children with cancer.

Here at LLS, beating cancer is in our blood. Over the past 70 years, we have invested nearly $1.3 billion in cutting edge research worldwide, fueling virtually every critical advancement in blood cancer treatment, including pioneering chimeric antigen receptor (CAR) T-cell immunotherapies that supercharge patients’ own immune cells to attack cancer. Many of these groundbreaking treatment approaches, first discovered in blood cancer, are now being tested in clinical trials for other cancers and diseases, such as breast, lung, pancreatic and prostate cancer.

We believe there is no one way to beat cancer. The future of cancer treatment hinges on giving the right treatment to the right patient at the right time. LLS is bringing the promise of precision medicine and immunotherapy to more patients in urgent need across every aspect of our mission work.

At the same time, we are relentless about helping patients, caregivers and families throughout their entire cancer experience to ensure they have access to care. LLS is the leading source of free blood cancer information, education and support for patients, survivors, caregivers, families and healthcare professionals. And through our nationwide CELEBRATING 70 YEARS

A Letter from our Leadership
grassroots network of more than 50,000 active online volunteers, we drive lifesaving policies that accelerate the development of new cancer treatments and break down barriers to care.

While we’ve made incredible progress, blood cancers are the second leading cause of cancer deaths in the U.S.—a sobering reminder that we have more work to do. We need to change fundamentally how children with cancer are treated. We need to advance new and efficient clinical trial models to deliver more breakthroughs, and importantly, we need to help patients access these trials. And we need to take bold action for patients against the staggering cost of cancer care.

Every facet of our mission is working in harmony to put patients first and address these priorities. As a global leader in the fight to end cancer, with your support, we press on with unwavering dedication.

Gratefully,

Louis J. DeGennaro, PhD
President and Chief Executive Officer

Jorge Benitez
Chair of the Board

“Everyone is supposed to fulfill a certain purpose in life; Robbie’s seems to have been to make others happy with his joyful, inspiring nature, his wit and knowledge, and as young as he was—in fact hardly more than a child—to earn the right not to be forgotten.”

— Rudolph Roesler de Villiers
SPOTLIGHTING OUR **IMPACT**

Our work has helped millions impacted by cancer.

Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled. What’s more, we’ve seen an average decline of 32 percent in blood cancer death rates since the 1990s. That’s the power of the LLS mission. By funding pioneering cancer research to advance treatments and cures and helping patients and families access the care they need, we are saving and improving the lives of patients and giving hope to countless families across the globe. But we won’t stop until we achieve a world without blood cancer.

“Thanks to LLS, a new treatment was available each time I relapsed, and those new treatments provided hope for my family and me.”

— Peter Pearson, a three-time cancer survivor first diagnosed with Hodgkin lymphoma in 2013

Peter participated in a clinical trial for a targeted therapy called brentuximab vedotin (Adcetris®), which LLS-funded research helped advance. In 2018, the FDA approved this therapy in combination with chemotherapy to treat newly diagnosed patients with advanced Hodgkin lymphoma, representing the first change in the standard of care for the disease in 40 years. Today, Peter and his family raise funds for LLS through Big Climb, Light The Night and Pennies for Patients.
Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled.

We’ve seen an average decline of 32 percent in blood cancer death rates since the 1990s.

NEARLY $1.3B INVESTED IN BLOOD CANCER RESEARCH WORLDWIDE SINCE 1949

LEADING SOURCE OF FREE EDUCATION AND SUPPORT FOR BLOOD CANCER PATIENTS AND FAMILIES

MORE THAN 50,000 ACTIVE ONLINE VOLUNTEERS ADVOCATE FOR LIFESAVING POLICIES
ADVANCING OUR MISSION IN 2019

Thanks to you, our 70th year was the most impactful one yet at LLS.

LLS HELPED ADVANCE
46 OF THE 53
BLOOD CANCER TREATMENT OPTIONS
APPROVED BY THE U.S. FOOD AND
DRUG ADMINISTRATION (FDA)
SINCE 2017.

IN ADDITION TO OUR BEAT AML MASTER
CLINICAL TRIAL, LLS SUPPORTED
MORE THAN 240
CUTTING EDGE RESEARCH GRANTS AND
22
THERAPY ACCELERATION PROGRAM (TAP)
PARTNERSHIPS WORLDWIDE.

LLS HAS SEEN PROGRESS ON
75 PERCENT
OF THE 31 POLICY RECOMMENDATIONS
WE PUT FORTH TO CONGRESS,
AIMED AT LOWERING THE COST OF
CANCER CARE FOR PATIENTS WHILE
PROTECTING ACCESS TO QUALITY CARE.

LLS VOLUNTEER ADVOCATES SENT
MORE THAN 8,400
LETTERS IN SUPPORT OF THE CANCER
DRUG PARITY ACT, INTRODUCED TO CONGRESS
TO ENSURE ACCESS TO ALL CANCER
TREATMENTS, REGARDLESS OF HOW
TREATMENTS ARE ADMINISTERED.

WHAT’S THE LATEST IN
BLOOD CANCER RESEARCH?

Lee Greenberger, PhD, Chief Scientific Officer at LLS,
shares what key trends mean for patients.

1. The genomics revolution is here. Blood cancers—which consist of more than 100 different types of diseases—are complex, but we’re cracking the code, thanks to new genomic technologies. Equipped with powerful molecular methods and a deeper understanding of our genetic blueprint, we’re learning more about what causes blood cancer and why certain therapies work and why some fail.
Your support helped LLS invest **$283.9 MILLION** in our mission this year, bolstering research, education and support, and policy and advocacy efforts that helped put patients and their families first.

**LLS INFORMATION SPECIALISTS**
- **RESPONDED TO** MORE THAN 20,000 INQUIRIES FROM PATIENTS AND CAREGIVERS IN 2019 ALONE.

**LLS CLINICAL TRIAL NURSE NAVIGATORS PROVIDED**
- MORE THAN 600 PATIENTS WITH IN-DEPTH CLINICAL TRIAL NAVIGATION AND SUPPORT.

**THIS YEAR, OUR LIGHT THE NIGHT, MAN & WOMAN OF THE YEAR AND STUDENTS OF THE YEAR CAMPAIGNS BROKE FUNDRAISING RECORDS**
- AS DEDICATED PARTICIPANTS DROVE MORE SUPPORT FOR OUR MISSION THAN EVER BEFORE.

**THANKS TO OUR INCREDIBLE SUPPORTERS, WE ACHIEVED OUR $125 MILLION FUNDRAISING GOAL FOR OUR COMPREHENSIVE EFFORTS TO BEAT ACUTE MYELOID LEUKEMIA (AML).**

**2. Precision medicine is on the rise.** Chemotherapies destroy cancer cells, but also damage normal cells, causing substantial side effects. Today, more recently approved oral targeted therapies attack blood cancer cells specifically, while sparing healthy cells with impressive results. For example, the FDA-approved combination of venetoclax (Venclexta®) and obinutuzumab (Gazyva®) marks a new chemotherapy-free, front-line treatment for chronic lymphocytic leukemia. LLS has supported research advancing venetoclax for the past 15 years. Venetoclax, when used in combination with conventional chemotherapy, is also a game changer for AML.

**3. The golden age of immunotherapy continues.** LLS is advancing different approaches that activate the immune system to fight cancer, including CAR T-cell immunotherapies and cancer vaccines. We’re exploring every avenue to improve CAR T-cell therapy so that more patients with blood cancer achieve long-lasting disease control.

**4. Prevention is the new frontier.** Advances in genomics are allowing us to identify individuals who are at a higher risk of developing blood cancer years before it might occur with the use of a blood test. Researchers are also exploring how to prevent early precursor diseases from progressing to more serious blood cancers.
I stand in defiance against childhood cancer. Losing my son Zach was unimaginably devastating, but his struggle makes me all the more relentless about accelerating better treatments and care, so we can save the lives of more children and spare others from life-altering, long-term side effects.”

— Julie Guillot, Volunteer Chair, Pediatric Partnerships and Outreach at LLS

**BY THE NUMBERS**

Approximately 80% of childhood cancer survivors develop one or more chronic health conditions as a result of treatment.

In the last 40 years, only 4 oncology drugs have been approved for first use in children.
Taking on Children’s Cancer from Every Direction

Fighting for Children with Cancer

Julie Guillot never imagined the harrowing struggle that would follow after her eldest son, Zach, was diagnosed with acute myeloid leukemia (AML) at the age of 5. For four years, Zach endured brutal chemotherapy, radiation, fevers, unyielding nausea and months confined to three different hospitals. A fan of superheroes, he faced the daunting regimen with bravery. But the intensity of his treatments took a tremendous toll. Sadly, Zach passed away after his third bone marrow transplant. “I won’t stop fighting for Zach. I am determined to do as much as I can so other families don’t have to go down this terrible path,” says Julie. Today, Julie is an influential parent advocate and LLS volunteer who is dedicated to speeding safer, more curative therapies for children.

Delivering Cures and Better Care

For many childhood cancers, chemotherapies developed decades ago remain the standard of care and simply don’t work well enough. Too many children succumb to their cancer. Survival rates for high-risk forms of blood cancer, such as AML, are especially poor. For those who do survive, the long-term effects of treatment can cause life-threatening complications and secondary illnesses and cancers.

LLS is disrupting the status quo with our bold vision: we want children not only to survive cancer, but thrive in their lives after treatment. That’s why we launched The LLS Children’s Initiative: Cures and Care for Children with Cancer, a full-scale, multi-year endeavor to take on children’s cancer from every direction.

“Every young life lost to cancer is one too many. We must do better. With The LLS Children’s Initiative, we will,” says Gwen Nichols, MD, LLS Chief Medical Officer.
Overcoming Obstacles to Progress

For too long, children have been treated with a one-size-fits-all approach, despite cancer behaving differently in children than in adults. “Children are not little adults; they need therapies that are designed just for them,” says Dr. Nichols. But given the relatively small patient population, there has not been enough incentive for the private sector to pursue pediatric drug development.

Beyond research, there are regulatory hurdles and access issues, including financial and geographic barriers, which stand between patients and the care they need.

Only LLS has the proven track record, leadership and visionary supporters needed to usher in a new era of pediatric cancer treatment and care.

**Our goal is to revolutionize the standard of care for children with cancer, providing them with safer, more effective treatments that rely less on chemotherapies that harm healthy cells in the body.**

When a child is diagnosed with cancer, it affects the entire family. The support we received from the two LLS programs helped us focus on taking care of King and made us feel less alone in our journey. King has been dealing with cancer for most of his young life, and has a long road ahead of him still. But we are hopeful that with LLS leading the charge, more children will survive cancer and thrive in their lives after treatment.

— Shameeza Singh, King’s mother

King was diagnosed with high-risk acute lymphoblastic leukemia (ALL) in June 2016 at the age of 2. His treatment plan included three and a half years of daily chemotherapy. He took 75 pills per month, in addition to intravenous and spinal chemotherapy. During this time, he experienced severe complications, including brain swelling, nerve damage, painful mouth sores and more. His family received support from LLS through our Urgent Need Program and Patient Aid Program. In October 2019, King completed chemotherapy, but continues to battle the chronic side effects from his treatment and a lifelong genetic disorder called G6PD deficiency. King and his family spend their time advocating and spreading awareness about pediatric cancer.
SPECIAL THANKS TO OUR CHILDREN’S INITIATIVE SUPPORTERS

Founding Partners
$1 million and above
Anonymous
The Harry T. Mangurian Jr. Foundation
Joan and Paul Rubschlager
The Wawa Foundation

$500,000–$999,999
The Don & Lorraine Freeberg Foundation
Lynne and Greg O’Brien
WWE

$250,000–$499,999
Anonymous (2)
Amgen Inc.
Orokawa Foundation
University of California San Francisco
University of Colorado Anschutz Medical Campus
University of Florida

$100,000–$249,999
Sara Asma & the Moore Family
William and Tamea Bock
The Boldt Family Philanthropy Fund
The Escher Foundation
F.M. Kirby Foundation
The Family and Friends of the Bock Family
Higgins Family Charitable Foundation
James and Lisa LaTorre
Nimick Forbesway Foundation

$10,000–$99,999
Anonymous
ACE Family Foundation
John Scott Black
Angela Blank
Bobby & Steve’s Auto World Youth Foundation
The Breyfogle Family
Charles and Chris Carroll
CURE Childhood Cancer
Kim Dobbs
Enquirer Foundation
The Family of Kent Ribordy
Dianne Franco
Herber Family/High Five Foundation
Jack Buncher Foundation
Kristen and Doug Johanson
The Kayleen Larson Legacy Foundation
Janice and Larry Lowder
Lydia Odle
Marla Persky and Craig Heberton
Cherie and Fredrick Pond
Robert Post
Andrea Reid
Brent and Barbara Reid
The Rhoda and David Chase Foundation
Dr. Skip and Amy Sands
Christine Schumacher and Hal Hess
Lori and Richard Turbe

Austin has been cancer free for six years, thanks to an LLS-supported CAR T-cell immunotherapy.
Taking on Children’s Cancer from Every Direction (cont.)

The LLS Children’s Initiative will bring precision medicine to children with cancer and ensure they have access to care.

Driving New Breakthroughs Faster

LLS is more than doubling our investment in pediatric cancer research grants worldwide. Our areas of focus include:

- Harnessing the immune system to fight cancer
- Identifying biomarkers to understand which patients will respond to certain therapies
- Overcoming treatment resistance
- Improving detection of cancer cells left after treatment that can lead to relapse
- Mitigating long-term treatment effects, such as cardiotoxicity and infertility

Further, LLS has undertaken an unprecedented collaboration to launch the first global precision medicine clinical trial for pediatric acute leukemia, called LLS PedAL. Building upon our successful Beat AML® Master Clinical Trial, LLS will unite physicians, scientists, regulators, advocacy organizations, pharmaceutical and biotechnology companies and others to change the paradigm of treatment through a precision medicine approach that puts pediatric patients first. Together, we will create a single set of pediatric cancer data that will be made available to researchers worldwide, identify and validate underlying molecular drivers of disease, and match patients with relapsed acute leukemia to the most promising treatments based on their unique tumor biology. The goal is to test multiple targeted therapies simultaneously at up to 200 clinical sites worldwide, with an anticipated opening in 2020.

Ensuring Access to the Best Care Possible

Because new breakthroughs are beneficial only if patients can access them, we are expanding our trusted education and support services—including resources for children and young adults with cancer and financial assistance programs—to help more patients, parents and caregivers navigate cancer treatments and access quality care. LLS is dedicated to helping children and families cope with the financial, emotional and psychological impact of a cancer diagnosis through our comprehensive array of free information, education and support.

Meanwhile, our policy and advocacy efforts focus on breaking down barriers to care and accelerating the development of new cancer treatments. LLS is co-chairing the Policy Committee of the Alliance for Childhood Cancer, a coalition of more than 25 advocacy groups and professional organizations. Through our work with the coalition, we played an instrumental role in the enactment of The Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, the most comprehensive federal childhood cancer legislation ever introduced.
Myrrah, leukemia survivor
"I was inspired by past LLS Career Development Program awardees, many of whom are now leaders in the field. This award from LLS provides a tremendous boost to our research."

— G. Greg Wang, PhD, University of North Carolina Lineberger Comprehensive Cancer Center

Dr. Wang is using a cutting edge gene-editing tool called CRISPR, combined with genetic profiling, to understand how a particular mutation called DNMT3A leads to the development of AML. With these insights, researchers can develop innovative new treatment strategies.
Accelerating Cures

Leading the Way to Cures

Our growing understanding of the genetic underpinnings of blood cancer is breaking new ground in cancer treatment and care. By supporting the full spectrum of research, from basic, laboratory-based science to large-scale clinical trials, LLS is at the forefront of the fight to cure cancer. At the same time, we’re working tirelessly to ensure that treatment advances reach blood cancer patients. LLS is redoubling efforts to connect patients to clinical trials, which are critical avenues to improving access to care and discovering breakthroughs. Further, our Office of Public Policy works to increase research funding at the National Institutes of Health (NIH) and other federal agencies, accelerate FDA approval processes while still protecting patient safety, and promote patient-focused drug development that prioritizes patients’ needs and concerns.

Investing in Pioneering Research

LLS is the largest nonprofit funder of blood cancer research. In 2019, we dedicated $47.4 million to support scientific grants, including 106 new grants awarded to researchers across the globe. With more than 35 new Career Development Program grants, we continue to bolster the early careers of scientists. Our support of promising young scientists has produced three Nobel Prize winners, more than 15 National Academy of Sciences members and more than 10 department chairs of major cancer centers.

LLS invested $7 million of our 2019 research budget in our Therapy Acceleration Program® (TAP), a venture philanthropy model through which we partner with biotech and academic institutions to advance promising novel therapies. New TAP partners include industry leaders such as Forty Seven, Inc., Sutro Biopharma, X4 Pharmaceuticals, Inc. and Verastem Oncology. Since 2017, three TAP-supported treatments were approved by the FDA.

Collaborating for Cures

LLS is driving innovative multi-year partnerships to maximize our research investment, including:

- A $1.8 million partnership with the Snowdome Foundation and Australia’s Leukaemia Foundation to support leading blood cancer research projects in Australia
- A $6.75 million collaboration between LLS, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group to boost critical discovery research by seasoned investigators
- A $4 million partnership with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) to accelerate global immunotherapy and prevention research
- A $1.5 million partnership with the RUNX1 Foundation to advance better treatments for RUNX1 familial platelet disorder
Championing Immunotherapy

Our more than 20-year investment in CAR T-cell immunotherapy has paid off with two approved treatments for children and young adults with acute lymphoblastic leukemia (ALL) and adults with certain highly lethal lymphomas who have exhausted all other treatment options. Remarkably, many patients remain free of disease years after a single CAR T-cell dose. Today, we are funding the next generation of this game changing approach:

- **Helen Heslop, MD, Baylor College of Medicine**, is driving new immunotherapies for leukemia, lymphoma and myeloma. Her visionary team is maximizing approved CAR T-cell immunotherapies and developing “off the shelf” CAR-Ts that use cells from donors instead of patients to reduce production time.

- **Jianhua Yu, PhD, City of Hope**, is combining CAR-T and bispecific antibodies, two living drugs that launch persistent immune responses against cancer cells, to treat myeloma.

Based on the success in blood cancer, researchers are investigating applications in solid tumors, including lung, breast, colon and prostate cancer.

Outsmarting Cancer with Precision Medicine

LLS is unifying goals among science, industry, cancer centers, regulators, philanthropists and patients to revolutionize cancer treatment through precision medicine. Our Beat AML Master Clinical Trial is a case in point. Launched in 2016, the Beat AML Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each AML patient’s cancer-driving genetic mutations, and then matches patients to the most promising targeted treatment within a rapid timeframe. More than 760 patients have been screened in 11 study arms at 16 cancer centers across the country.

Other highlights include:

- **Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center**, and his colleagues are studying the unique molecular features of patients with myeloma precursor diseases, so treatment can be tailored to prevent progression to full-blown myeloma.

- **Ari Melnick, MD, Weill Cornell Medicine**, is advancing novel therapies for B-cell lymphomas that target specific epigenetic mechanisms, the switches that turn genes on or off and control cell behavior.

- **Craig Jordan, PhD, University of Colorado**, is leading a world-class team of researchers to eradicate cancer stem cells—the roots of disease—in patients with AML through personalized approaches. This work is supported by a matching fund from the University of Colorado Medical Center.
LLS’s early and sustained research investment in CAR T-cell immunotherapy is the reason I am here today and able to cherish every moment with my daughter.

— Chuck Colletti, diagnosed with non-Hodgkin lymphoma in 2016

This year, Chuck fundraised proudly for LLS through our Man & Woman of the Year campaign.
Driving Clinical Trial Innovation, Education and Enrollment

Understanding the Value of Clinical Trials

Without sufficient enrollment in clinical trials, new treatments cannot be approved, scientific knowledge stalls and patients cannot access potentially lifesaving therapies. But the landscape is complex and evolving rapidly. Patients and caregivers are often left to search for trials on their own, leaving them with more questions than answers. The process can be cumbersome for healthcare professionals, too. Clinical research in the era of precision medicine is homing in on smaller groups of patients with specific disease subtypes or characteristics. Too many trials fail to meet their goals because there are not enough patients enrolled. Clinical trials are not “last resort” options, but rather avenues to leading edge care. LLS is committed to connecting patients to clinical trials, funding groundbreaking clinical science and advocating for policies that put patients at the center of their care.

Improving Access and Participation

LLS continues to expand our Clinical Trial Support Center (CTSC), in which Clinical Trial Nurse Navigators—registered nurses with expertise in blood cancers—conduct comprehensive clinical trial searches and assist patients and caregivers throughout the entire clinical trial enrollment process. Together, LLS Clinical Trial Nurse Navigators and LLS Information Specialists—master’s level oncology professionals—work one-on-one with blood cancer patients and caregivers to help them become more active participants in their care and overcome barriers to enrolling in trials, including assistance with finances and lodging.

On average, it takes more than 30 interactions with a patient, their caregivers and healthcare professionals to help a patient enroll in a clinical trial. This year, LLS Clinical Trial Nurse Navigators had nearly 8,000 interactions with patients, caregivers and healthcare professionals, demonstrating the depth and breadth of our support.

With only about 5 percent of all adult cancer patients in the U.S. enrolling in clinical trials, LLS is helping to bridge this enrollment gap with our free, personalized clinical trial navigation for blood cancer patients and their families. Typically, 22 percent of patients who are assisted by the CTSC enroll in an appropriate clinical trial, showing the power of our in-depth support on the lives of patients.
I was on a mission to stay alive. The treatment options at the time were few, lacked effectiveness and had difficult side effects. After enduring six different treatments over 12 years, I achieved a complete remission finally, thanks to a clinical trial for an LLS-supported CAR T-cell immunotherapy.

— Laurie Adami, diagnosed with non-Hodgkin lymphoma in 2006

She has set the goal of participating in Team In Training’s Climb 2 Cure at Mount Everest Base Camp in spring 2020.

LLS offers a wide array of free education and support for patients, caregivers and healthcare professionals.

- LLS Clinical Trial Nurse Navigators
- LLS Information Specialists
- Weekly online chats
- Peer-to-peer support

- Online social network called LLS Patient Community
- Financial assistance
- Nutrition consultations
- Caregiver support
- Webcasts

- Videos
- Podcasts
- Information booklets
- Continuing Education/Continuing Medical Education programs
Looking Forward

Beginning in 2020, LLS will expand a dynamic collaboration with the American Society of Hematology (ASH) to provide more than 2,500 ASH member physicians in the U.S. and Canada with dedicated access to the CTSC, making it easier to refer patients to our personalized support. This collaboration builds upon a successful pilot program completed in 2018, which found that the CTSC helped physicians have informed discussions with their patients about clinical trials as a possible course of treatment.

LLS is also working to expand clinical trial access among blood cancer patients in underserved communities. Through our new research program, Impactful Medicine Providing Access to Clinical Trials (IMPACT), we aim to bring innovative clinical trials to patients served by community cancer centers, especially in rural or economically disadvantaged areas. By fostering partnerships between community-based oncologists and clinical trial leaders at major cancer centers, IMPACT will help patients access clinical trials in their communities and educate local physicians about advances in genomics and precision medicine. The goal of each IMPACT grant is to increase clinical trial participation among blood cancer patients served by community cancer centers by at least 20 percent over a five-year period.

Pioneering New Models

LLS funds research from bench to bedside through collaborations, venture philanthropy and grants. This year, we invested $32 million of our research budget to support clinical trials, along with an additional $10.5 million to operate our Beat AML Master Clinical Trial, for a total investment of $42.5 million. Complementing our research agenda are policy and advocacy efforts that push for affordable clinical trial access and hold the FDA accountable for implementing clinical trial reforms enacted in the 21st Century Cures Act, including new rules on master trials.

LLS champions these pioneering models. Our Beat AML Master Clinical Trial demonstrates that personalized treatment using genomics can be assigned to patients based on their specific subtype in less than seven days. With its flexible, collaborative structure, the trial is testing several novel therapies in multiple study arms simultaneously. This patient-first trial design—developed with guidance from the FDA—has the potential to stand as a model for future cancer clinical trials. Now, LLS will bring our leadership in patient-centric clinical trials to pediatric acute leukemia and other blood cancers. We will also continue to ensure that patients’ needs and preferences are at the forefront of drug development to pave the way for better care and cures in the future.

LLS-funded researcher Selina Chen-Kiang, PhD, Weill Cornell Medicine, and her world-class team
“I was armed with so much information. When you have information, you feel empowered. Every day, we learned more and that helped Meaghan take ownership of her health. I’d encourage anyone going through a blood cancer diagnosis to reach out to LLS. There is such an incredible network of support, and it’s so much better when you have someone in your corner.”

— Maura Kilner, a caregiver for her daughter Meaghan, who was diagnosed with Hodgkin lymphoma in 2017

As a 2019 Honored Hero for Students of the Year, Meaghan inspired and motivated high school students in her community to raise funds for our mission.
Helping Patients Throughout Their Cancer Experience

Approximately every three minutes, someone in the U.S. is diagnosed with a blood cancer. When someone experiences the fear and uncertainty of a cancer diagnosis, we provide hope, guidance, education and support. LLS is dedicated to helping patients navigate their cancer treatments and access quality care.

Supporting Patients, Caregivers and Families

We are committed to patients, caregivers and families throughout their entire cancer experience. Here at LLS, we believe one-on-one support makes all the difference, so we offer a wide array of free resources to help patients find the support they need.

For more than two decades, LLS Information Specialists have been on the front lines of an ever-changing healthcare landscape, guiding patients and caregivers to our robust education and support services. Information Specialists are master’s level oncology professionals who provide free, personalized assistance to patients, families and healthcare providers. They offer guidance through cancer treatment, assist with financial and social challenges, and give accurate, up-to-date disease, treatment and support information. Information Specialists also refer patients to LLS Clinical Trial Nurse Navigators as appropriate.

According to an independent evaluation that concluded in 2019, 86 percent of patients and caregivers said they felt more hopeful and 83 percent said they felt more comfortable managing their or their loved one’s diagnosis after their first contact with an Information Specialist. This is an extraordinary testament to the impact of LLS’s one-on-one support.

We offer a variety of ways for patients and caregivers to find connections and support. This year, LLS:

- Connected more than 1,500 volunteers with patients and caregivers diagnosed with the same disease through LLS’s Patti Robinson Kaufmann First Connection Program
- Reached nearly 12,000 patients and caregivers registered on our online social network, LLS Patient Community
- Provided nearly 900 patients and caregivers with free, personalized nutrition consultations from our registered dietitian
- Distributed a new, comprehensive caregiver workbook in English and Spanish to 930 caregivers

Contact an Information Specialist for one-on-one support at 1.800.955.4572, and by live chat or email via www.LLS.org.
Volunteering with Myeloma Link gave me a way to heal from my cancer experience, while helping someone else in the process. A diagnosis is a stumbling block, but there is light at the end of the tunnel. For me, the support and education I received from LLS has been that light.

— Kelvin Yates, diagnosed with myeloma in 2014

In addition to providing direct support to patients, Kelvin participates in Light The Night.
Helping Patients Throughout Their Cancer Experience (cont.)

Educating Patients, Caregivers and Healthcare Professionals

LLS is here to help patients, caregivers and healthcare professionals stay informed and current on the latest disease, treatment and survivorship information. This year, LLS:

- Distributed more than 855,000 educational booklets and fact sheets about blood cancers and survivorship topics
- Educated more than 132,400 patients, caregivers, healthcare professionals and others through live web-based and local in-person programs
- Reached nearly 12,000 listeners through LLS podcasts, including *The Bloodline with LLS* for patients and caregivers, and *Treating Blood Cancers*, a new podcast for healthcare professionals

Investing in Health Services Research

LLS plans to boost our investment in health services research to understand and address concerns about quality of life and access to care during treatment and beyond. LLS is pursuing research into:

- The financial burden of treatment
- The services survivors or caregivers might need
- The preferences patients have when weighing treatment options
- The late effects survivors might be experiencing

This year, LLS received a three-year grant to fund a new intervention study by Carma Bylund, PhD, University of Florida, and her research team that aims to improve family and healthcare communication among adults who care for a parent with blood cancer. This work builds upon in-depth qualitative research completed by Dr. Bylund and LLS in 2018, which identified unique communication issues faced by these caregivers, including conflicts with siblings in negotiating caregiving responsibilities and navigating role reversals. As part of the intervention study, new online resources will launch on www.LLS.org in the next year to help caregivers of parents practice open, healthy communication with their families, find reliable cancer information online and communicate effectively with healthcare teams. Both research studies were funded by the Carolan Research Institute.

SPOTLIGHT ON MYELOMA LINK

African Americans have twice the incidence of myeloma as white Americans. Recent studies show that African Americans are significantly less likely to receive the latest treatments, and are more likely to experience treatment delays. LLS is dedicated to connecting African American communities to free myeloma information and support and enhancing access to care and the latest treatments through our Myeloma Link program. In 2019, the program expanded from two to eight cities, reaching more than 10,000 patients, caregivers and healthcare providers through over 100 awareness and education programs. Myeloma Link is just one part of our efforts to address the needs of underserved communities. LLS has committed $35.4 million in multi-year grants to accelerate impactful myeloma research to find cures.
LLS invests in research critical to achieving cancer treatment breakthroughs, which often requires decades of effort and financial support. While LLS is advancing efficient clinical trial designs and cost effective ways to produce groundbreaking treatments, we need to take action now to ensure that cancer patients can access lifesaving treatments.

Taking Bold Action for Patients

With the cost of cancer care skyrocketing, a growing portion of these costs is being shifted to patients. As a result, some patients are delaying or even forgoing treatment. Through our nationwide grassroots network of more than 50,000 active online volunteers, LLS works to break down barriers standing between patients and the care they need.

In 2017, LLS launched our Cost of Cancer Care Initiative with aggressive, yet feasible cost-cutting ideas that would save money without sacrificing quality care. We shared our ideas with stakeholders across the healthcare ecosystem because we believe all players need to do their part to put patients first.

Since then, our Office of Public Policy has made significant progress on many fronts, including:

- Bi-partisan support for proposals to lower out-of-pocket costs, especially for those enrolled in Medicare Part D
- Measures under consideration to promote value-based payments, so that the cost of service reflects its value
- Measures adopted to increase marketplace competition, such as allowing generic drugmakers to introduce less expensive versions of costly drugs sooner

LLS also advocates for meaningful health insurance coverage, so that patients can afford the treatments they need. We advance solutions that uphold our core principles for meaningful coverage: guarantee access, promote affordability, ensure quality and encourage stability.

In particular, LLS calls upon lawmakers to limit the spread of short-term, limited duration health insurance plans, which pose risks to patients and consumers by requiring them to pay exorbitant costs. We pushed back against these plans through multifaceted efforts, urging members of Congress, governors, state legislators and insurance commissioners to take action to protect patients.

While legislators debated proposals that would roll back access to meaningful health insurance coverage, LLS took action.

**Breaking Down Barriers to Care**

**PROTECTING MEANINGFUL HEALTH INSURANCE**

- MORE THAN 16,700 LETTERS SENT BY LLS ADVOCATES
- MORE THAN 725 COMPLETED CALLS MADE BY LLS ADVOCATES
- HUNDREDS OF IN-PERSON MEETINGS CONDUCTED WITH POLICYMAKERS
“Policy change is needed to ensure that the patients I work with can access the care they need to live long and healthy lives. I’m proud to raise my voice with LLS and speak out on behalf of patients and their families.”

— Myra Davis-Alston, a passionate LLS volunteer advocate who brings her unique perspective as an oncology nurse to our policy and advocacy endeavors
Breaking Down Barriers to Care (cont.)

While we fight the rising cost of cancer care through our policy and advocacy endeavors, we know patients and caregivers need help now. We provide an array of financial assistance programs to help with cancer-related expenses.

Making a Difference

Through our financial assistance programs, we help patients and families navigate difficulties with insurance and co-pay burdens and cope with the often daunting financial challenges of cancer treatment. This year, LLS expanded the financial support we provide through two new programs to help blood cancer patients and their families when they need it most.

• The LLS Urgent Need Program, established in partnership with “Moppie’s Love,” is available to help pediatric and young adult blood cancer patients, or adult blood cancer patients enrolled in clinical trials, who are in acute financial need. The program provides a $500 grant to assist with non-medical expenses, including utilities, rent, mortgage, food, lodging, dental care, child care, elder care and other essential needs.

• The LLS Patient Aid Program provides financial assistance to blood cancer patients, regardless of their financial circumstances. Eligible patients receive a $100 stipend.

What patients and families are saying:

“Without your financial and moral support, I wouldn’t be alive today. You help put food on my table and hope in my heart.”

“LLS has been a wonderful help when a tough financial spot arose from our daughter’s long in-patient stay. The $500 [from the LLS Urgent Need Program] helped with our rent.”

“Your program has been a saving grace for my parents. They planned for retirement and would have had everything wiped out had it not been for your service.”
Uncovering New Insights

Here at LLS, we believe no one should have to choose between seeking care and affording groceries or a mortgage. The cost of cancer care is becoming unsustainable for both cancer patients and the overall healthcare system. LLS is investing in more research to understand the financial burdens associated with the cost of blood cancer treatment and its long-term effects, as well as disparities in patients’ access to the latest treatments. Leading edge LLS-funded research projects include:

- **Rena Conti, PhD, Associate Research Director of Biopharma & Public Policy at the Boston University Institute for Health System Innovation & Policy**, is leading a study to understand better the range of financial difficulties experienced by patients with multiple myeloma or chronic lymphocytic leukemia who are undergoing or have forgone treatment at National Cancer Institute Community Oncology Research Program (NCORP) Minority/Underserved Community Sites across the country. Dr. Conti is also a Dean’s Research Scholar and Associate Professor of Markets, Public Policy and Law at the Boston University Questrom School of Business.

- **Stacie Dusetzina, PhD, Associate Professor of Health Policy and Ingram Associate Professor of Cancer Research at Vanderbilt**, is leading a two-year study jointly funded by LLS and The Commonwealth Fund on the impact of healthcare costs on the behavior of senior patients enrolled in Medicare. Her research is examining the association between delaying or never filling specialty drug prescriptions and health outcomes related to the disease being treated.

In addition, we commissioned two studies by the actuarial firm, Milliman, examining the factors that are driving blood cancer costs within the healthcare system as well as the out-of-pocket cost burden that patients experience. The findings showed, for example, that treatment of acute leukemia among commercially insured patients cost the healthcare system more than $800,000 on average in the first three years following a patient’s diagnosis. For patients with Medicare coverage, those being treated for lymphoma spent as much as $19,000 out-of-pocket on medical costs in the first year following their diagnosis, while those with myeloma spent $24,000 on average in the first two years following diagnosis.

These extraordinary costs underscore the simple fact that meaningful insurance coverage is a necessity for virtually anyone in need of blood cancer treatment. The high cost of care is also a reminder that as we make advancements in the treatment of blood cancer, we must pursue policies that ensure those treatments are accessible to the patients who need them. To learn more about our Cost of Cancer Care Initiative, please visit www.LLS.org/cancercost.
For generations of families and children, our signature fundraising campaigns have helped LLS find cures and ensure access to treatments for blood cancer patients nationwide. We are inspiring people across the country to run, hike, walk, sail, build teams and gain lifelong learning skills while raising funds to drive forward our mission. This year, LLS is featured once again in The Chronicle of Philanthropy’s “America’s Favorite Charities,” and jumped from number 61 last year to number 39 in 2019, showcasing one of the highest growth rates in charitable contributions (34 percent). Among charities with a health focus, LLS is ranked sixth on the list.

For more than 30 years, LLS has been a pioneer in creating unique and innovative peer-to-peer fundraising campaigns. The Leukemia Cup Regatta, a thrilling series of events that combines the joy of on-water sports with the important task of raising money to cure cancer, commenced in 1988. Skippers and their crews participate in more than 45 regattas nationwide.

LLS’s flagship campaign Team In Training® was formed in 1988. From there, Team In Training has gone on to set the standard for endurance sports fundraising programs worldwide. More than 650,000 teammates have run, walked, hiked, cycled, climbed and competed in triathlons.

Man & Woman of the Year, a philanthropic competition, launched in 1990. Now taking place in nearly 100 communities across the country, the campaign brings together a passionate group of individuals and their teams for an exciting 10-week philanthropic competition to win the title of “Man or Woman of the Year.”
Since 1993, children have experienced the satisfaction that comes from helping others by fundraising in honor of local, school-aged patients battling blood cancers. More than 14.5 million students, families and educators in 27,000 schools across the U.S. participate annually in programs, such as Pennies for Patients.

Light The Night® kicked off nationwide in 1999 and is now the fifth largest peer-to-peer fundraising program in the U.S. One million friends, families and co-workers gather together and bring light to the darkness of cancer, carrying illuminated lanterns in 140 inspirational evening walks to celebrate, honor or remember those touched by cancer.

New innovative fundraising campaign Students of the Year launched nationally in 2017 and is helping to foster committed young philanthropists and redefine what giving looks like in today’s charity and community service environment.

LLS Lifestyle, initiated in 2017, is a new peer-to-peer fundraising platform that enables LLS supporters to get creative and start their own movement. In its inaugural year, participants turned their creative ideas into impactful fundraising activities in support of LLS.
We are grateful to our partners and sponsors, who harness the power of their consumers, communities and employees to help fight blood cancers. Some of our top partners include:

**Burlington Stores, Inc.**

For the past 17 years, LLS has partnered with Burlington to host an in-store point-of-sale campaign that raises funds to further the LLS mission. Through this campaign, Burlington associates ask customers to donate $1 or more at checkout to raise critical funds for research and patient support that help to save lives and bring smiles to the faces of children and families impacted by blood cancer. Burlington is our number one National Corporate Partner and Honored Friend, having raised more than $37 million since 2002.

**United Food and Commercial Workers Union (UFCW)**

UFCW takes great pride in the longstanding partnership with LLS—37 years and more than $90 million raised. The Labor Against Cancer initiative, launched in 2017, features a fundraising drive among members, retail campaigns and walking to end cancer with LLS’s Light The Night, and represents an unprecedented effort to mobilize more than one million members and their families to build awareness and help raise funds.

**Walgreens**

Walgreens has been collaborating with and supporting LLS since 2016, providing education and resources for patients and their families who are living with blood cancer; this includes training and certification for specialty pharmacists and sponsoring our Blood Cancer Conferences. Walgreens' commitment extends far beyond patient and professional education. Last year, more than 6,500 Walgreens stores participated in fundraisers that raised $2.6 million for LLS. Nearly 250 Walgreens teams around the country also participated in Light The Night.
Subaru

Together, Subaru retailers and local LLS staff deliver co-branded blankets and arts and crafts kits to adults and children fighting cancer along with “message of hope” cards signed by visitors to the retailers, offering words of encouragement and hope. Since 2016, LLS and Subaru have donated more than 148,000 blankets and 21,500 arts and crafts kits and reached nearly 150,000 patients in more than 780 hospitals, with the help of more than 540 Subaru retailers nationwide.

WAWA

Wawa and The Wawa Foundation are proud partners of LLS, holding in-store customer engagement fundraising each year to benefit Light The Night. In 2018, The Wawa Foundation committed to presenting-level sponsorship support in both Philadelphia and Washington, D.C. Additionally, the Foundation recently announced a $1 million grant to The LLS Children’s Initiative to accelerate new and better treatments for pediatric blood cancers.
Celebrating a Beat AML Victory

This year, LLS achieved a historic milestone: we met our ambitious fundraising goal of $125 million for Beat AML. Donors, volunteers, supporters, Beat AML project leads, and LLS staff and leadership gathered to celebrate at two festive events: one in New York City and the other in San Francisco.

Hosting the events, Dr. Louis DeGennaro declared: “I call it a victory, because that is exactly what this is. We took on the challenge of leading a global initiative to find new treatments for a cancer that had not seen real progress in four decades. And because of all of you, we are victorious and will continue to fight this battle.”

The evenings highlighted how this, the first-ever capital campaign held by LLS, is a real game-changer—and not just for LLS but for the entire medical field. With our donors and partners, Beat AML advanced novel science and validated a revolutionary master clinical trial model that puts patients at the center of the research paradigm.

And, it opened the door for further advances in acute myeloid leukemia through continued Beat AML efforts, as well as the launch of The LLS Children’s Initiative.

Beat AML demonstrates the power of philanthropy at LLS.

Honoring the life and contribution of campaign vice-chair, John Kellenyi, Michael Copley, national chair, spoke of John’s impact. “The campaign would not have been the same without John,” said Michael. “He was the most amazing fundraiser, friend and human being. John took tremendous pride in knowing what he did furthered the LLS mission by improving and saving the lives of patients.”

From left: Cristina Kellenyi, Dr. Louis DeGennaro, Teresita Kellenyi, Michael Copley

“Our son Michael passed away in 2008 from AML and our goal is to support better treatments and results through the work of LLS and the Beat AML initiative. We want people who are diagnosed with AML to know that there is hope!”
— Kelly Treinen, The Michael Treinen Foundation, Noblesville, Indiana

“After losing our beloved son and brother Robert Lyon to AML in 2007, we dedicated our family foundation to supporting AML research to ensure that those facing
the same diagnosis have far better odds at beating the disease. With the Beat AML initiative in full swing, the Lyon Family Foundation is even more focused on disrupting the current trajectory for these patients and seeing treatment change at a really rapid rate!"

— Lyon Family, Chicago, Illinois

“Women are changing the world through our growing leadership and strategic philanthropy. Collectively we’re going to have a greater impact than alone. That is why we have launched Women Curing Cancer, a community of women seeking to accelerate cancer cures, especially for children. We believe the way to cure cancer is to identify the best and brightest researchers and support the most innovative and promising projects. Together, we can drive incredible progress in science and medicine.”

— Lynne O’Brien and Evelyn Bata, PhD, Co-founders, Women Curing Cancer

Women Curing Cancer is a group of women leaders who are partnering with LLS to accelerate cancer cures.

“When I was diagnosed with CLL in 2001, I knew nothing about the disease or what it meant for my future. LLS provided the information I requested and put me in touch with my local chapter. That was the beginning of a long and wonderful relationship. Wanting to give back to LLS, I became a volunteer and later Trustee for the chapter and formed a Family & Friends team to participate in the annual Light The Night walk. My brother and sister-in-law, Steve and Maddy, have been incredibly generous over the years with their own philanthropy to LLS. We want our help to continue after us, so both Paul and I have named LLS in our will. Steve and Maddy established an annuity with LLS that will serve the same purpose.”

— Helen Anbinder, New York

“My journey with LLS began in 2008 right after going through the frightening diagnosis of non-Hodgkin lymphoma. I heard about LLS’s Team in Training and I felt I could use my personal experience to raise money for a more than worthy cause. I later served on the Long Island Chapter’s Board of Trustees and learned about the funding needed for research, which is the only way to find a cure for all blood cancers. I decided to make a personal gift directly to research while also continuing my fundraising crusade for Team In Training. LLS has changed my life and will always be a part of my life as well as my family’s.”

— Gary Trovato, Long Island
Acknowledging Our Extraordinary Volunteers

Our lifesaving work would not be possible without volunteers. Each day, volunteers across the country give their time and talent to activities that support our mission. Their efforts are game changing: they provide the leadership, big ideas and dedication we need to beat cancer.

LLS volunteers are part of a diverse and vibrant community of supporters who represent all walks of life and bring different experiences and passions to drive forward our mission. With countless ways to engage, from raising critical funds, to advocating for lifesaving policies, to providing support to those impacted by cancer, our volunteers are truly making a difference.

Since we started in 1949, the partnerships between volunteers and staff have been at the heart of our quest to find cancer cures. That’s why LLS is committed to recognizing and engaging volunteers who support every facet of our organization.

This year, LLS launched Volunteers in Action (VIA), a new online and mobile platform that will help us do exactly that. VIA empowers volunteers throughout their journey with LLS, connecting them to the tools, resources and people they need to create impact. With VIA, volunteers can see the impact of their time, sign up for the latest opportunities and interact with staff and other volunteers who share their interests.

If you volunteer with LLS or have in the past, thank you for your incredible partnership. You inspire us to work tirelessly toward our mission every single day.

If beating cancer is in your blood, we have a rewarding volunteer opportunity for you – whatever your interests, skills or time commitments.

Learn more at www.volunteerLLS.org.
“We’ve met amazing people through LLS and built so many relationships, especially with Man & Woman of the Year candidates—some of whom are survivors themselves. And we’ve met others who don’t have a connection, but just want to help. Becoming part of the LLS community has been such an amazing experience for our family.”

— Rachel Dacanay-Smith, mother of Lucia, who was diagnosed with acute promyelocytic leukemia in 2018

After enduring an intense, nine-month treatment regimen, Lucia’s cancer went into complete remission. As the 2019 Girl of the Year for LLS’s National Capital Area Chapter, Lucia inspired Man & Woman of the Year candidates to raise significant funds and awareness.
Independent Auditors’ Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2019, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Emphasis of Matter
As discussed in note 1(t) to the consolidated financial statements, in 2019 The Leukemia & Lymphoma Society, Inc. adopted new accounting guidance, Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. Our opinion is not modified with respect to this matter.

Report on Summarized Comparative Information
We have previously audited the The Leukemia & Lymphoma Society, Inc. 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated November 7, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived before the adjustments to adopt Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. As part of our audit of the 2019 consolidated financial statements, we also audited the adjustments described in note 1(t) that were applied to adopt Accounting Standards Update 2016-14, Presentation of Financial Statements of Not-for-Profit Entities retrospectively in the 2018 consolidated financial statements. In our opinion, such adjustments are appropriate and have been properly applied.

November 5, 2019

KPMG LLP
### Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2019 (with comparative amounts at June 30, 2018) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$24,735</td>
<td>$27,628</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>4,653</td>
<td>2,767</td>
</tr>
<tr>
<td>Contribution and other receivables, net (note 7)</td>
<td>15,489</td>
<td>32,255</td>
</tr>
<tr>
<td>Investments (note 4)</td>
<td>407,903</td>
<td>319,662</td>
</tr>
<tr>
<td>Fixed assets, net (note 10)</td>
<td>9,161</td>
<td>8,614</td>
</tr>
<tr>
<td>Total assets</td>
<td>$461,941</td>
<td>$390,926</td>
</tr>
</tbody>
</table>

|               |          |          |
| **Liabilities and Net Assets** |          |          |
| Liabilities:  |          |          |
| Accounts payable and accrued expenses | $23,487  | $21,907  |
| Deferred revenue (note 8) | 13,739   | 16,243   |
| Awards and grants payable (note 2) | 50,974   | 51,673   |
| Co-Pay assistance payable (note 3) | 94,957   | 54,696   |
| Other long-term liabilities (note 11) | 4,715    | 3,835    |
| Total liabilities | $187,872 | $148,354 |

Commitments and contingencies (notes 2, 3, 12 and 14)

Net assets:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>178,099</td>
<td>149,199</td>
</tr>
<tr>
<td>With donor restrictions (notes 3 and 6)</td>
<td>95,970</td>
<td>93,373</td>
</tr>
<tr>
<td>Total net assets</td>
<td>$274,069</td>
<td>$242,572</td>
</tr>
</tbody>
</table>

Total liabilities and net assets

$461,941  $390,926

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019  
(with summarized totals for the year ended June 30, 2018) (In thousands)

### Operating revenue:

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$273,691</td>
<td>20,832</td>
<td>294,523</td>
<td>282,108</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(29,624)</td>
<td></td>
<td>(29,624)</td>
<td>(29,198)</td>
</tr>
<tr>
<td></td>
<td><strong>Net campaign contributions</strong></td>
<td>244,067</td>
<td>20,832</td>
<td>264,899</td>
</tr>
<tr>
<td>Co-Pay contributions (note 3)</td>
<td>-</td>
<td>90,930</td>
<td>90,930</td>
<td>159,851</td>
</tr>
<tr>
<td>Therapy Acceleration Program contractual return</td>
<td>4,495</td>
<td></td>
<td>4,495</td>
<td>3,855</td>
</tr>
<tr>
<td>Service revenue</td>
<td>14,936</td>
<td></td>
<td>14,936</td>
<td>9,230</td>
</tr>
<tr>
<td>Donated services, goods and media (note 9)</td>
<td>11,987</td>
<td></td>
<td>11,987</td>
<td>7,715</td>
</tr>
<tr>
<td>Legacies and other revenue</td>
<td>6,721</td>
<td>13,187</td>
<td>19,908</td>
<td>11,018</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>5,265</td>
<td>1,921</td>
<td>7,186</td>
<td>4,316</td>
</tr>
<tr>
<td>Net assets released from restrictions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Pay assistance (note 3)</td>
<td>102,057</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>22,456</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total operating revenue</td>
<td><strong>411,984</strong></td>
<td>2,357</td>
<td><strong>414,341</strong></td>
<td><strong>448,895</strong></td>
</tr>
</tbody>
</table>

### Operating expenses:

**Program services:**

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>71,119</td>
<td></td>
<td>71,119</td>
<td>66,865</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>153,138</td>
<td></td>
<td>153,138</td>
<td>162,707</td>
</tr>
<tr>
<td>Public health education</td>
<td>45,130</td>
<td></td>
<td>45,130</td>
<td>39,557</td>
</tr>
<tr>
<td>Professional education</td>
<td>14,500</td>
<td></td>
<td>14,500</td>
<td>16,425</td>
</tr>
<tr>
<td>Total program services</td>
<td><strong>283,887</strong></td>
<td></td>
<td><strong>283,887</strong></td>
<td><strong>285,554</strong></td>
</tr>
</tbody>
</table>

**Supporting services:**

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>54,258</td>
<td></td>
<td>54,258</td>
<td>44,698</td>
</tr>
<tr>
<td>Fund raising</td>
<td>49,101</td>
<td></td>
<td>49,101</td>
<td>42,342</td>
</tr>
<tr>
<td>Total supporting services</td>
<td><strong>103,359</strong></td>
<td></td>
<td><strong>103,359</strong></td>
<td><strong>87,040</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total operating expenses</td>
<td><strong>387,246</strong></td>
<td></td>
<td><strong>387,246</strong></td>
<td><strong>372,594</strong></td>
</tr>
<tr>
<td>Change in net assets from operating activities</td>
<td>24,738</td>
<td>2,357</td>
<td>27,095</td>
<td>76,301</td>
</tr>
<tr>
<td>Foreign currency translation adjustment and other</td>
<td>(38)</td>
<td>1</td>
<td>(37)</td>
<td>(99)</td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>4,200</td>
<td>239</td>
<td>4,439</td>
<td>7,060</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td><strong>28,900</strong></td>
<td>2,597</td>
<td><strong>31,497</strong></td>
<td><strong>83,262</strong></td>
</tr>
</tbody>
</table>

**Net Assets:**

<table>
<thead>
<tr>
<th></th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total 2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of period</td>
<td><strong>149,199</strong></td>
<td>93,373</td>
<td><strong>242,572</strong></td>
<td><strong>159,310</strong></td>
</tr>
<tr>
<td>End of period</td>
<td><strong>$178,099</strong></td>
<td>95,970</td>
<td><strong>274,069</strong></td>
<td><strong>242,572</strong></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019 (with comparative totals for the year ended June 30, 2018) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Year ended</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research</td>
<td>Patient and community service</td>
<td>Public health education</td>
<td>Professional education</td>
</tr>
<tr>
<td>Awards and grants</td>
<td>$45,687</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Therapy acceleration program</td>
<td>2,433</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>10,468</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>—</td>
<td>4,228</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay assistance</td>
<td>—</td>
<td>97,151</td>
<td>—</td>
<td>97,151</td>
</tr>
<tr>
<td>Co-Pay processing fees</td>
<td>—</td>
<td>4,088</td>
<td>—</td>
<td>4,088</td>
</tr>
<tr>
<td>Donated services, goods and media</td>
<td>628</td>
<td>2,572</td>
<td>3,786</td>
<td>222</td>
</tr>
<tr>
<td>Salaries and employee benefits</td>
<td>4,969</td>
<td>27,744</td>
<td>22,993</td>
<td>8,505</td>
</tr>
<tr>
<td></td>
<td>4,755</td>
<td>4,803</td>
<td>4,606</td>
<td>2,042</td>
</tr>
<tr>
<td></td>
<td>133</td>
<td>3,611</td>
<td>5,809</td>
<td>1,046</td>
</tr>
<tr>
<td></td>
<td>222</td>
<td>3,147</td>
<td>2,775</td>
<td>908</td>
</tr>
<tr>
<td></td>
<td>614</td>
<td>2,221</td>
<td>2,056</td>
<td>1,005</td>
</tr>
<tr>
<td></td>
<td>1,005</td>
<td>739</td>
<td>336</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>1,408</td>
<td>1,693</td>
<td>229</td>
</tr>
<tr>
<td></td>
<td>174</td>
<td>1,285</td>
<td>949</td>
<td>368</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>141</td>
<td>127</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>$71,119</td>
<td>153,138</td>
<td>45,130</td>
<td>14,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
### Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (In thousands)

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$31,497</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>(3,497)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>4,364</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>396</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(1,886)</td>
</tr>
<tr>
<td>Contributions and other receivables, net</td>
<td>16,370</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>1,580</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>880</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(2,504)</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>(699)</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>40,261</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>86,762</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities:** |           |
| Purchases of fixed assets | (4,911) | (3,994) |
| Purchases of long-term investments | (92,600) | (150,533) |
| Sales of investments | 7,856 | 47,633 |
| Net cash used in investing activities | (89,655) | (106,894) |
| Net decrease in cash and cash equivalents | (2,893) | (13,773) |

Cash and cash equivalents at beginning of period | 27,628 | 41,401 |
Cash and cash equivalents at end of period | $24,735 | 27,628 |

See accompanying notes to consolidated financial statements.
1) Organization and Summary of Significant Accounting Policies

(a) Organization

The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

(b) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty-six chapters in the United States, and LLS’s not for profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. Effective February 8, 2018, PPCS was dissolved. All significant intercompany and intra LLS accounts and transactions have been eliminated in consolidation.

(c) Tax-Exempt Status

LLS, LLSRP and LLSRF qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS and its related entities recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2019 and 2018.

(d) Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include allocation of expenses, and valuation of donated goods, services and media. Actual results could differ from those estimates.
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(e) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is contributions by the general public. Accordingly, LLS’s operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co Pay program in 2019 and 2018 was funded by six donors, respectively. In addition, the Beat AML Master Trial was primarily funded by seven donors in 2019 and 2018, respectively.

(f) Summarized Financial Information

The consolidated financial statements are presented with 2018 summarized information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2018 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2018 consolidated financial statements from which the summarized information was derived.

(g) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2019 through November 5, 2019, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

(h) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into two net asset categories as follows:

Net assets without donor restrictions: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.

Net assets with donor restrictions: Consist of funds that are restricted by donors for a specific time period and/or purpose. Also included in this category are net assets subject to donor imposed restrictions, which stipulate that the principal be maintained by LLS, but permits LLS to expend part or all of the income and gains derived there from. Expirations of restrictions are reported as net assets released from restrictions when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 6).

Revenue and gains and losses on investments and other assets and liabilities are reported as changes in net assets without restrictions unless limited by explicit donor imposed restrictions or by law. Expenses are reported as decreases in net assets without donor restrictions.

LLS delineates changes in net assets without donor restrictions as operating or non operating activities. Operating activities include all operating revenues and expenses that are an integral part of its programs and supporting activities and net assets released from donor restrictions to support operating expenditures. The measure of operations include support for operating activities from both with donor restrictions and without donor restrictions designated for long term investment according to LLS’s spending rate policy (note 6). Non operating activities include changes in fair value of investments and foreign currency translation adjustment and other nonrecurring items.

(i) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

(continues »)
(j) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- **Level 1** inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- **Level 2** inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- **Level 3** unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

(k) Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as revenues with donor restrictions. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of activities as net assets released from restrictions.

Contributions expected to be received after one year are discounted at a risk adjusted rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor imposed restrictions, if any, on the contributions.

Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(l) Service Revenue

Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(m) Donated Goods and Services

LLS has determined that certain of the donated goods and services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 9).
(n) Donated Media

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSA’s (note 9).

(o) Cash Equivalents

Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

(p) Investments

Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

(q) Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years; and computer equipment and software 2 to 5 years).

(r) Other Long Term Liabilities

Other long term liabilities represent LLS’s liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 11), straight line rent of office leases (note 12), and capital leases.

(s) Professional Fees

Professional fees included in the consolidated financial statements principally include professional fund raising fees, contracted software development, and legal and auditing fees.

(t) Adopted Accounting Pronouncements

The FASB issued Accounting Standards Update (ASU) 2016 14, Presentation of Financial Statements of Not for Profit Entities, which among other things, changes how not for profit entities report net asset classes, expenses and liquidity in their financial statements. LLS adopted the main provisions of this guidance which include, the reduction of the number of net asset classes from three to two: with donor restrictions, previously reported as temporarily restricted net assets of $90,221 and permanently restrictions net assets of $3,152, in 2018, and without donor restrictions, previously reported as unrestricted net assets of $149,199, in 2018; the presentation of expenses by their function and their natural classification in one location; and quantitative and qualitative information about the management of liquid resources and availability of financial assets to meet cash needs within one year of the balance sheet date.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(u) Upcoming Accounting Standards

ASU No. 2014 09, Revenue from Contract with Customers (Topic 606) – This ASU, effective for LLS’s fiscal year ending June 30, 2020, will require LLS to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which LLS expects to be entitled in exchange for those goods or services. Management is evaluating the effect ASU 2014 09 will have on its consolidated financial statements.

ASU No. 2018 08, Not for Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contribution Received and Contributions Made – This ASU, effective for the LLS’s fiscal year ending June 30, 2020, is intended to clarify how entities determine whether to account for a transfer of assets (or a reduction, settlement, or cancellation of a liability) as an exchange transaction or a contribution based on whether commensurate value has been received or transferred. The new guidance also clarifies that a contribution is conditional if the agreement includes both a barrier that must be overcome for the recipient to be entitled to the assets transferred and a right of return for the transferred assets or a right of release of a promisor’s obligation to transfer assets. Management is evaluating the effect ASU 2018 08 will have on its consolidated financial statements.

ASU No. 2016 02, Leases (Topic 842) – This guidance, effective for LLS’s fiscal year ending June 30, 2022, requires a lessee to recognize a right of use asset and a lease liability, initially measured at the present value of the lease payments on the consolidated balance sheet and disclosing key information about leasing arrangements. Management is evaluating the effect ASU 2016 02 will have on its consolidated financial statements.

(v) Functional Allocation of Expense

The costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly certain costs attributable to more than one program or supporting services function are allocated using cost allocation methods such as square footage and estimate of time and effort.

LLS allocates expenses relating to the operation and maintenance of plant and depreciation using building square footage based on functional use.

2) Research

LLS has various activities that are utilized to carry out its mission as presented below:

Research:
Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi year grant commitments of $39,093 at June 30, 2019, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $50,974 and $51,673 at June 30, 2019 and 2018, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $1,665 and $984 as of June 30, 2019 and 2018, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP):
TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $14,471 and $12,745 at June 30, 2019 and 2018, respectively, that are conditioned upon future events and, accordingly, are not recorded. Grant refunds of approximately $320 and $591 as of June 30, 2019 and June 30, 2018, respectively have been netted against therapy acceleration program contractual return.

(continues »)
Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

Year ending June 30:

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023 and thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$30,206</td>
<td>17,868</td>
<td>5,323</td>
<td>167</td>
<td>$53,564</td>
</tr>
</tbody>
</table>

For the year ended June 30, 2019 and 2018, LLS received $4,495, and $3,855 of TAP contractual returns from various TAP contracts.

3) Co-Pay Assistance Program

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance Co-Pay obligations for prescription medications or private/public health insurance premiums. Revenue is recognized when donations are received while expenses are recognized as patient applications are approved for participation according to program criteria and on availability of funding. The Co-Pay Assistance payable of $94,957 and $54,696 has been established based on approved patient applications received through June 30, 2019 and 2018, respectively. At June 30, 2019, net assets with donor restrictions include $43,279 received through June 30, 2019, which are available for expenditure and are intended to be awarded in future periods.

The following summarizes the activities of the Co-Pay Assistance program as of June 30, 2019.

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2019</th>
<th>June 30, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$52,528</td>
<td>8,148</td>
</tr>
<tr>
<td>Contributions</td>
<td>90,930</td>
<td>159,851</td>
</tr>
<tr>
<td>Investment Gains</td>
<td>1,878</td>
<td>326</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(97,151)</td>
<td>(108,442)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(4,906)</td>
<td>(7,355)</td>
</tr>
<tr>
<td>Amounts available for expenditures in subsequent periods</td>
<td>$43,279</td>
<td>52,528</td>
</tr>
</tbody>
</table>

(continues »)
4) Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2019 and June 30, 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$239,287</td>
<td>239,287</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>63,201</td>
<td>63,201</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>39,198</td>
<td>39,198</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>26,695</td>
<td>26,695</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>26,273</td>
<td>26,273</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>4,935</td>
<td>4,935</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>399,589</td>
<td>399,589</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Investments reported at NAV:
- Multi strategy hedge funds: $8,314

Total: $407,903

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$158,371</td>
<td>158,371</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>56,758</td>
<td>56,758</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>849</td>
<td>849</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>35,644</td>
<td>35,644</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>33,437</td>
<td>33,437</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>22,872</td>
<td>22,872</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>3,665</td>
<td>3,665</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>311,596</td>
<td>311,596</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Investments reported at NAV:
- Multi strategy hedge funds: $8,066

Total: $319,662

Within the investment balance as of June 30, 2019 and June 30, 2018 are $123,297 and $89,492 restricted to Co-Pay, respectively.
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

LLS’s alternative investments strategy:

_multistyle hedge funds_ – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.

This strategy creates indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2019 and 2018, the following table summarizes the redemption provisions for those investments reported at NAV:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly</td>
<td>$1,600</td>
<td>—</td>
</tr>
<tr>
<td>Quarterly</td>
<td>4,000</td>
<td>6,380</td>
</tr>
<tr>
<td>Semi-Annual</td>
<td>1,000</td>
<td>—</td>
</tr>
<tr>
<td>Annual</td>
<td>1,714</td>
<td>1,686</td>
</tr>
<tr>
<td>Total</td>
<td>$8,314</td>
<td>8,066</td>
</tr>
</tbody>
</table>

As of June 30, 2019 and 2018, LLS had no unfunded commitments on its alternative investments.

5) **Financial Assets**

LLS goal is to maintain financial assets to meet the requirements of all outstanding commitments, excluding Co-Pay, both current and conditional as well as a minimum of 25–50% of annual general expenditures. LLS considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures, excluding expenditures related to LLS Co-Pay Program. As part of LLS liquidity plan, excess cash is invested in short term investments, including money market accounts, fixed income and equities.

In addition to available financial assets, LLS operates with a balanced budget and anticipates collecting sufficient revenue to cover all general expenditures. Refer to the statement of cash flows, which identifies the sources and uses of LLS’ cash and shows positive cash generated by operations for fiscal years 2019 and 2018.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

The following represents LLS’s financial assets as of June 30, 2019:

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 24,735</td>
</tr>
<tr>
<td>Contributions and other receivable</td>
<td>15,489</td>
</tr>
<tr>
<td>Investments</td>
<td>407,903</td>
</tr>
<tr>
<td>Total financial assets</td>
<td>448,127</td>
</tr>
</tbody>
</table>

Less amounts not available to be used within one year:

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and other receivable with donor restrictions not to be met in less than a year</td>
<td>$ 9,485</td>
</tr>
<tr>
<td>Alternative investments with redemptions greater than 12 months</td>
<td>1,714</td>
</tr>
<tr>
<td>Equity holdings not expected to be redeemed</td>
<td>8,866</td>
</tr>
<tr>
<td>Restricted to support Co-Pay patients</td>
<td>138,538</td>
</tr>
<tr>
<td>Perpetual donor restriction</td>
<td>3,117</td>
</tr>
<tr>
<td>Total financial assets not available for use</td>
<td>161,720</td>
</tr>
</tbody>
</table>

Financial assets available to meet general expenditures within one year of the balance sheet date

$ 286,407

6) Net assets with donor restrictions

Net assets with donor restrictions and the income earned are available for the following purposes at June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$ 8,501</td>
<td>8,977</td>
</tr>
<tr>
<td>Patient and Community Service</td>
<td>4,544</td>
<td>4,609</td>
</tr>
<tr>
<td>Public Health Education</td>
<td>3,579</td>
<td>2,572</td>
</tr>
<tr>
<td>Professional Education</td>
<td>3,599</td>
<td>2,783</td>
</tr>
<tr>
<td>Beat AML Initiative</td>
<td>23,611</td>
<td>14,750</td>
</tr>
<tr>
<td>Children’s Initiative</td>
<td>2,905</td>
<td>851</td>
</tr>
<tr>
<td>Beat AML Master Trial</td>
<td>5,623</td>
<td>6,144</td>
</tr>
<tr>
<td>Co-Pay</td>
<td>43,279</td>
<td>52,528</td>
</tr>
<tr>
<td>Other</td>
<td>329</td>
<td>159</td>
</tr>
<tr>
<td>Total net assets with donor restriction</td>
<td>$95,970</td>
<td>93,373</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2019 and 2018 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$6,577</td>
<td>6,282</td>
</tr>
<tr>
<td>Investment income</td>
<td>304</td>
<td>551</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>2</td>
<td>(7)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(303)</td>
<td>(249)</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$6,580</td>
<td>6,577</td>
</tr>
</tbody>
</table>

7) Contribution and other receivables

LLS’s contribution and other receivables at June 30, 2019 and June 30, 2018 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met.

Contributions and other receivables consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$2,909</td>
<td>1,539</td>
</tr>
<tr>
<td>Other restricted contributions</td>
<td>11,627</td>
<td>15,266</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>—</td>
<td>15,100</td>
</tr>
<tr>
<td>Service revenue</td>
<td>953</td>
<td>350</td>
</tr>
<tr>
<td>Total</td>
<td>$15,489</td>
<td>32,255</td>
</tr>
</tbody>
</table>

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$11,027</td>
<td>24,400</td>
</tr>
<tr>
<td>One to five years</td>
<td>6,287</td>
<td>10,076</td>
</tr>
<tr>
<td></td>
<td>17,314</td>
<td>34,476</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(641)</td>
<td>(987)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5.0%)</td>
<td>(1,184)</td>
<td>(1,234)</td>
</tr>
<tr>
<td>Total</td>
<td>$15,489</td>
<td>32,255</td>
</tr>
</tbody>
</table>

As of June 30, 2019 and 2018, 39% and 77% of contributions and other receivables were from one and two funding sources, respectively.

8) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end. Deferred revenue as of June 30, 2019 and 2018 consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special events</td>
<td>$11,782</td>
<td>12,386</td>
</tr>
<tr>
<td>Service revenue</td>
<td>1,957</td>
<td>3,857</td>
</tr>
<tr>
<td></td>
<td>13,739</td>
<td>16,243</td>
</tr>
</tbody>
</table>

9) Donated Services, Goods and Media

The value of donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated goods</td>
<td>$1,616</td>
<td>1,483</td>
</tr>
<tr>
<td>Donated services</td>
<td>2,924</td>
<td>2,950</td>
</tr>
<tr>
<td>Donated media</td>
<td>7,447</td>
<td>3,282</td>
</tr>
<tr>
<td>Total</td>
<td>$11,987</td>
<td>7,715</td>
</tr>
</tbody>
</table>

(continues »)
10) Fixed Assets, Net

Fixed assets at June 30, 2019 and 2018 consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$ 2,577</td>
<td>2,079</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>4,725</td>
<td>4,154</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>43,073</td>
<td>39,231</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>50,375</td>
<td>45,464</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(41,214)</td>
<td>(36,850)</td>
</tr>
<tr>
<td><strong>Fixed assets, net</strong></td>
<td>$ 9,161</td>
<td>8,614</td>
</tr>
</tbody>
</table>

11) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $2,432 and $2,336 for the years ended June 30, 2019 and 2018, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2019 and 2018. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately $1,747 and $1,586 at June 30, 2019 and 2018, respectively. The liabilities of the 457 Plans are included in other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately $1,747 and $1,586 at June 30, 2019 and 2018, respectively.

12) Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$7,395</td>
<td>5,733</td>
<td>3,364</td>
<td>10,433</td>
<td>8,522</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>43,539</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
13) Joint Costs Allocation

For the years ended June 30, 2019 and 2018, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$10,150</td>
<td>7,463</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>2,978</td>
<td>3,496</td>
</tr>
<tr>
<td>Public health education</td>
<td>7,164</td>
<td>4,884</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$20,292</td>
<td>15,843</td>
</tr>
</tbody>
</table>

14) Contingent Liabilities

LLS is a defendant in various lawsuits arising in the normal course of business. Management does not expect the ultimate resolution of these actions to have a material adverse effect on LLS’s financial position.
ACKNOWLEDGMENTS
Research Grants

Specialized Center of Research

The Specialized Center of Research program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

John Cleveland, PhD, 2019
H. Lee Moffitt Cancer Center & Research Institute
Madhav Dhodapkar, MBBS, 2020* Emory University
Dr. Madhav Dhodapkar is jointly funded by Emory University
Helen Heslop, MD, 2019
Baylor College of Medicine
Craig Jordan, PhD, 2019
University of Colorado Denver, Anschutz Medical Campus
Dr. Craig Jordan is jointly funded by the University of Colorado Denver, Anschutz Medical Campus
Carl June, MD, 2020*
The Trustees of the University of Pennsylvania, Medical Center
Jonathan Licht, MD, 2020* University of Florida
Tak Mak, PhD, 2017
University Health Network
Ari Melnick, MD, 2016
Joan & Sanford I. Weill Medical College of Cornell University
Dr. Ari Melnick is funded in part by Joan & Sanford I. Weill Medical College of Cornell University and donations from the Estcher Foundation, the Jim Jacobs Foundation, the LIUNA Charitable Foundation, the Mellyre Foundation, and Angela and Gary Trotova.

Stephen Nimer, MD, 2018
University of Miami
Dr. Stephen Nimer is funded in part by donations from the Sylvester Comprehensive Cancer Center of the University of Miami.
Robert Orlowski, MD, PhD, 2018
The University of Texas MD Anderson Cancer Center
Andreas Strasser, PhD, FAA, MSc, 2018
Walter & Eliza Hall Institute of Medical Research
David Weinstock, MD, 2016
Dana-Farber Cancer Institute
Dr. David Weinstock is funded in part by a donation from Sandra Abbott
Anas Younes, MD, 2017
Sloan Kettering Institute for Cancer Research
Dr. Anas Younes is funded in part by donations from the Jewish Federation of Cleveland, Sandi and Stan Kahn, and Cathy and Scott Zeilinger.

Career Development Program (Scholars and Clinical Scholars)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Omar Abdel-Wahab, MD, 2017
Sloan Kettering Institute for Cancer Research
Arash Alizadeh, MD, PhD, 2020*
Board of Trustees of the Leland Stanford Junior University
Philippe Armand, MD, PhD, 2019
Dana-Farber Cancer Institute
Saro Armenian, DO, MPH, 2017
Beckman Research Institute of the City of Hope
Uttiya Basu, PhD, 2016
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Robert Bradley, MD, 2018
Fred Hutchinson Cancer Research Center
Dr. Robert Bradley is funded in part by a donation from S Lori Brown.
Jason Butler, PhD, 2019
Hackensack Meridian Health
Fernando Camargo, PhD, 2016
Boston Children's Hospital
Grant Challen, PhD, 2019
Washington University in St. Louis
Jianjun Chen, PhD, 2018
Beckman Research Institute of the City of Hope
Jerry Chipuk, PhD, 2017
Icahn School of Medicine at Mount Sinai
Tomek Cierpicki, PhD, 2017
Regents of the University of Michigan
Simona Colla, PhD, 2019
The University of Texas MD Anderson Cancer Center
Alexey Danilov, MD, PhD, 2019
Oregon Health & Science University
Matthew Davids, MD, 2019
Dana-Farber Cancer Institute
Dr. Matthew Davids is funded in part by Dana-Farber Cancer Institute and donations from Genentech and Imagine a Cure for Leukemia.
Lei Ding, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Todd Druley, MD, PhD, 2019**
Washington University in St. Louis
Takeshi Egawa, MD, PhD, 2018
Washington University School of Medicine in St. Louis
Areej El-Jawahri, MD, 2020*
Massachusetts General Hospital
Maria Figueroa, MD, 2019
University of Miami
Benjamin Garcia, PhD, 2016
Perelman School of Medicine at the University of Pennsylvania
Alfred Garfall, MD, 2020*
Perelman School of Medicine at the University of Pennsylvania
Ramiro Garzon, MD, 2016
The Ohio State University
Irene Ghobrial, MD, 2017
Dana-Farber Cancer Institute
Dr. Irene Ghobrial is jointly funded by Dana-Farber Cancer Institute.
David Guertin, PhD, 2016
University of Massachusetts Medical School
Alex Herrera, MD, 2019
Beckman Research Institute of the City of Hope
Dr. Alex Herrera is fully funded by a donation from Toni and Emmet Stephenson.
Katharine Hsu, MD, PhD, 2017
Sloan Kettering Institute for Cancer Research
Keisuke Ito, MD, PhD, 2019
Albert Einstein College of Medicine, Inc.
Peng Ji, MD, PhD, 2018
Northwestern University
Hao Jiang, PhD, 2019
University of Virginia
Alex Kentis, MD, PhD, 2020*
Sloan Kettering Institute for Cancer Research
Michael Kharas, PhD, 2018
Sloan Kettering Institute for Cancer Research
Kasey Leger, MD, 2020*
Seattle Children’s Hospital
Rong Lu, PhD, 2020*
University of Southern California
Dr. Rong Lu is jointly funded by the University of Southern California.
Ravindra Majeti, MD, PhD, 2016
Board of Trustees of the Leland Stanford Junior University

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019
Newly awarded or renewed grants in Fiscal Year 2020

Grantee prematurely terminated award in Fiscal Year 2019

Washington University in St. Louis
by donations from Atrium Health
Dr. Saad Usmani is funded in part
Atrium Health Foundation

Cincinnati Children’s Hospital
Daniel Starczynowski, PhD, 2016
Van Andel Research Institute

Vanderbilt University Medical Center
Christopher Park, MD, PhD, 2018
New York University School of Medicine
Daniel Polyrea, MD, 2020*
University of Colorado Denver, Anschutz Medical Campus
Zhijian Qian, PhD, 2019
University of Florida

Christiane Querfeld, MD, PhD, 2019
Beckman Research Institute of the City of Hope

Dr. Christiane Querfeld is fully funded by a donation from the Schwartz Ward Family Foundation.

Kerry Rogers, MD, 2020*
The Ohio State University
Michael Savona, MD, 2019
Vanderbilt University Medical Center

Xiaobing Shi, PhD, 2017
Van Andel Research Institute
Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center

Saad Usmani, MD, 2018
Atrium Health Foundation
Dr. Saad Usmani is funded in part by donations from Atrium Health Foundation.

Geoffrey Uy, MD, 2018
Washington University in St. Louis

Christopher Vakoc, MD, PhD, 2016
Cold Spring Harbor Laboratory
G. Greg Wang, PhD, 2019
The University of North Carolina at Chapel Hill
Jian Xu, PhD, 2020*
Children’s Medical Center Research Institute at UT Southwestern
Jianhua Yu, PhD, 2019
The Ohio State University/Beckman Research Institute of the City of Hope

Dr. Jianhua Yu is fully funded by a donation from the Schwartz Ward Family Foundation.

Amer Zeidan, MBBS, 2019
Yale University
Dr. Amer Zeidan is funded in part by Yale University and a donation from S Lori Brown.

Career Development Program (Special Fellows and Fellows)

Robert Albero Gallego, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Silvia Alvarez, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Brandon Aubrey, PhD, 2019
Dana-Farber Cancer Institute
Will Bailis, PhD, 2019**
Yale University
Yaël Ben-Nun, PhD, 2019
Dana-Farber Cancer Institute
Anat Biran, PhD, 2020*
Dana-Farber Cancer Institute
Juliette Bouyssou, PhD, 2020*
Dana-Farber Cancer Institute
George Burgess, PhD, 2018
Yale University
Chun-Chin Chen, PhD, 2020*
Joan & Sanford I. Weill Medical College of Cornell University
Pan-Yu Chen, PhD, 2019
The Regents of the University of California, San Francisco
Ryan Corces, PhD, 2018**
Board of Trustees of the Leland Stanford Junior University
Sondra Downey-Kopyscinski, PhD, 2020*
Dana-Farber Cancer Institute
Daphné Dupéré-Riché, PhD, 2019
University of Florida
Javier Garcia Bermudez, PhD, 2020*
Rockefeller University
Mitchell Geer, PhD, 2020*
New York University School of Medicine
Jennifer Grants, PhD, 2018
British Columbia Cancer Agency Branch
Zhaohui Gu, PhD, 2019
St. Jude Children’s Research Hospital
Annamaria Guilla, MD, 2020*
Dana-Farber Cancer Institute
Bingqian Guo, PhD, 2018**
Harvard Medical School
Lulu Hu, PhD, 2018
The University of Chicago
Daichi Inoue, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research/Foundation for Biomedical Research and Innovation at Kobe
Szuang Jiang, PhD, 2019
Board of Trustees of the Leland Stanford Junior University
Gloria Jhi, PhD, 2019
Regents of the University of Michigan/The Trustees of the University of Pennsylvania, Medical Center
Emily Johnston, MD, 2019
The University of Alabama at Birmingham
Courtney Jones, PhD, 2020*
University of Colorado Denver, Anschutz Medical Campus
Niraj Joshi, PhD, 2019
Dana-Farber Cancer Institute
Vishal Khairnar, PhD, 2020*
Beckman Research Institute of the City of Hope
Richard Jason Lamontagne, PhD, 2018
The Wistar Institute
Jianping Li, MD, 2020*
University of Florida
Shan Lin, PhD, 2020*
Dana-Farber Cancer Institute
Sydney Lu, MD, PhD, 2020*
Sloan Kettering Institute for Cancer Research
Priya Mathur, PhD, 2018
The University of Chicago
Demis Menolfi, PhD, 2019
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Linde Miles, PhD, 2019
Sloan Kettering Institute for Cancer Research
Coraline Mlynarczyk, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University
Lucia Morgado-Palacin, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center
Tomoya Muto, MD, PhD, 2019
Cincinnati Children’s Hospital Medical Center
Tamara Ouspenskaia, PhD, 2018
Broad Institute, Inc.
Erin Peckham-Gregory, PhD, 2020*
Baylor College of Medicine
Bibiana Rius, PhD, 2019
The Scripps Research Institute
Jacqueline Rivas, PhD, 2020*
University of Kentucky
Alejo Rodriguez Fraticelli, PhD, 2019
Boston Children’s Hospital
Julia Rogers, PhD, 2020*
Harvard Medical School
Alejandro Roisman, PhD, 2020*
University of Miami
Noha Sharafeldin, MD, PhD, 2019
The University of Alabama at Birmingham
Xianguo Shi, PhD, 2020*
Baylor College of Medicine
Ashima Shukla, PhD, 2018
Sanford Burnham Prebys Medical Discovery Institute
Vijju Shukla, PhD, 2018
La Jolla Institute for Allergy and Immunology
Erick Smith, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research
Dr. Eric Smith is funded in part by a donation from the Names Family Foundation.

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019
Sloan Kettering Institute for Cancer Research

**Newly awarded or renewed grants in Fiscal Year 2020**

- **Grantee prematurely terminated award in Fiscal Year 2019**

Alexandra Soukop, PhD, 2020*
University of Wisconsin at Madison

Pamela Sung, MD, PhD, 2020*
The Trustees of the University of Pennsylvania, Medical Center

Brian Sworder, MD, PhD, 2019
Board of Trustees of the Leland Stanford Junior University

Samuel Taylor, PhD, 2019
Albert Einstein College of Medicine, Inc.

Elisa ten Hacken, PhD, 2018
Dana-Farber Cancer Institute

Rachel Thijssen, PhD, 2018
Walter & Eliza Hall Institute of Medical Research

Daniel Utzschneider, PhD, 2019
The University of Melbourne

Leandro Venturutti, PhD, 2018
Joan & Sanford I. Weill Medical College of Cornell University

Andrew Volk, PhD, 2020*
Northwestern University

Ly Vu, PhD, 2019
Sloan Kettering Institute for Cancer Research

Adam Wilkinson, PhD, 2019
Board of Trustees of the Leland Stanford Junior University

Matthew Witkowski, PhD, 2018
New York University School of Medicine

Gongwei Wu, PhD, 2020*
Dana-Farber Cancer Institute

Min Xia, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University

Haopeng Yang, PhD, 2020*
The University of Texas MD Anderson Cancer Center

William Yewdell, PhD, 2019
Sloan Kettering Institute for Cancer Research

Christina Yim, PhD, 2020*
Sloan Kettering Institute for Cancer Research

Akhide Yoshimi, MD, PhD, 2019
Sloan Kettering Institute for Cancer Research

Noemi Zambetti, PhD, 2018
The Regents of the University of California, San Francisco

Jiajun Zhu, PhD, 2018
Sloan Kettering Institute for Cancer Research

Translational Research Program

The Translational Research Program supports outstanding investigators deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Iannis Alfantis, PhD, 2020*
New York University School of Medicine

Carl Allen, MD, PhD, 2018
Baylor College of Medicine

Stephen Ansell, MD, PhD, 2018
Mayo Clinic, Rochester

Dr. Stephen Ansell is funded in part by a donation from the Albrecht Family.

Scott Armstrong, MD, PhD, 2020*
Dana-Farber Cancer Institute

Fotis Asimakopoulos, MD, PhD, 2018
The Board of Regents of the University of Wisconsin System

Dr. Fotis Asimakopoulos is funded in part by a donation from the Greater Milwaukee Foundation.

Jon Aster, MD, PhD, 2018
Brigham and Women’s Hospital

Brian Baker, PhD, 2020*
University of Notre Dame

Venkata Lokesh Battula, PhD, 2020*
The University of Texas MD Anderson Cancer Center

Smita Bhatia, MD, MPH, 2019
The University of Alabama at Birmingham

Ranjit Bindra, MD, PhD, 2018
Yale University

Bruce Blazar, MD, 2018
University of Minnesota, Twin Cities

Patrick Brown, MD, 2020*
The Johns Hopkins University School of Medicine

Dr. Patrick Brown is jointly funded by Amgen, Inc.

Tomek Cierpicki, PhD, 2019**
Regents of the University of Michigan

George Daley, MD, PhD, 2018
Boston Children’s Hospital

Alexey Danilov, MD, PhD, 2018
Oregon Health & Science University

Hema Dave, MD, MPH, 2018
Children’s Research Institute

Kara Davis, DO, 2018
Board of Trustees of the Leland Stanford Junior University

Benjamin Ebert, MD, PhD, 2018
Dana-Farber Cancer Institute

Dr. Benjamin Ebert is funded in part by donations from The Babich Family Foundation.

Andrew Feldman, MD, 2019
Mayo Clinic, Rochester

Carolyn Felix, MD, 2019
The Children’s Hospital of Philadelphia

Adolfo Ferrando, MD, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

David Fruman, PhD, 2020*
University of California, Irvine

Terry Fry, MD, 2020*
University of Colorado, Denver

Karim Gaensler, MD, 2018
The Regents of the University of California, San Francisco

Jacqueline Garcia, MD, 2018
Dana-Farber Cancer Institute

Jolanta Grembecka, PhD, 2020*
Regents of the University of Michigan

Christian Grommes, MD, 2019
Sloan Kettering Institute for Cancer Research

Edwin Hawkins, PhD, 2018
Walter & Eliza Hall Institute of Medical Research

Camelia Iancu-Rubin, PhD, 2019
Mount Sinai School of Medicine at Mount Sinai

Babaj Jha, PhD, 2020*
Cleveland Clinic Foundation

Peng Ji, MD, PhD, 2020*
Northwestern University

Ricky Johnstone, PhD, 2020*
The University of Melbourne

Dr. Ricky Johnstone is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.

Justin Kline, MD, 2020*
The University of Chicago

Dr. Justin Kline is jointly funded by The University of Chicago.

Angela Koehler, PhD, 2018
Massachusetts Institute of Technology

Robert Kridel, MD, PhD, 2020*
University Health Network

Larry Kwak, MD, PhD, 2018
Beckman Research Institute of the City of Hope

Jatinder Lamba, PhD, 2020*
University of Florida

Ronald Levy, MD, 2018
Board of Trustees of the Leland Stanford Junior University

Timothy Ley, MD, 2018
Washington University School of Medicine in St. Louis

Yan Liu, PhD, 2020*
Indiana University

Ivan Maillard, MD, PhD, 2020*
The Trustees of the University of Pennsylvania, Medical Center

Ravindra Majeti, MD, PhD, 2019
Board of Trustees of the Leland Stanford Junior University

Sami Malek, MD, 2020*
Regents of the University of Michigan

Maksim Mamonkin, PhD, 2019
Baylor College of Medicine

Ari Melnick, MD, 2019
Joan & Sanford I. Weill Medical College of Cornell University

Soheil Meshinchi, MD, PhD, 2020*
Fred Hutchinson Cancer Research Center

Constantine Mitsiades, MD, PhD, 2018
Dana-Farber Cancer Institute

Gareth Morgan, MD, PhD, FRCP, FRCPath, 2020*
New York University School of Medicine

* Newly awarded or renewed grants in Fiscal Year 2020  
**Grantee prematurely terminated award in Fiscal Year 2019
Charles Mullighan, MD, 2020*  
St. Jude Children’s Research Hospital  

Dr. Charles Mullighan is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.

Ryotaro Nakamura, MD, 2020*  
Beckman Research Institute of the City of Hope  

Dr. Ryotaro Nakamura is jointly funded by Beckman Research Institute of the City of Hope.

Sattva Neelapu, MD, 2020*  
The University of Texas MD Anderson Cancer Center  

Stephen Nimer, MD, 2018  
University of Miami  

Dr. Stephen Nimer is funded in part by donations from The Babich Family Foundation.

Stephen Nutt, PhD, 2020*  
Walter & Eliza Hall Institute of Medical Research  

Dr. Stephen Nutt is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.

Owen O’Connor, MD, PhD, 2020*  
The Trustees of Columbia University in the City of New York, Columbia University Medical Center  

Dr. Owen O’Connor is jointly funded by The Trustees of Columbia University in the City of New York, Columbia University Medical Center.

Jae Park, MD, 2018  
Sloan Kettering Institute for Cancer Research  

Dr. Jae Park is funded in part by donations from Edith Klein, the Hairy Cell Leukemia Foundation, and The SASS Foundation for Medical Research, Inc.

Laura Pasqualucci, MD, 2019  
The Trustees of Columbia University in the City of New York - Morningside  

Joel Pomerantz, PhD, 2020*  
The Johns Hopkins University School of Medicine  

Sean Post, PhD, 2019  
The University of Texas MD Anderson Cancer Center  

Jun Qi, PhD, 2018  
Dana-Farber Cancer Institute  

Katy Rezvani, MD, PhD, 2018  
The University of Texas MD Anderson Cancer Center  

Rizwan Romee, MD, 2020*  
Dana-Farber Cancer Institute  

Steven Rosen, MD, 2019  
Beckman Research Institute of the City of Hope  

Davide Rossi, MD, PhD, 2020*  
Foundation for the Institute of Oncology Research  

Michael Rout, PhD, 2020*  
Rockefeller University  

Kathleen Sakamoto, MD, PhD, 2020*  
Board of Trustees of the Leland Stanford Junior University  

Deepa Sampath, MD, PhD, 2018  
The Ohio State University  

Guy Sauvageau, MD, PhD, FRCPC, 2018  
Institute for Research in Immunology and Cancer  

Dr. Guy Sauvageau is funded in part by donations from The Babich Family Foundation.

Barbara Savoldo, MD, 2018  
The University of North Carolina at Chapel Hill  

Mala Shanmugam, PhD, 2019  
Emory University  

Kevin Shannon, MD, 2020*  
The Regents of the University of California, San Francisco  

Dr. Kevin Shannon is jointly funded by The Regents of the University of California, San Francisco.

Additi Shastri, MD, 2020*  
Montefiore Medical Center  

Margaret Shipp, MD, 2020*  
Dana-Farber Cancer Institute  

Lev Silberman, MD, PhD, 2018  
Fred Hutchinson Cancer Research Center  

Tomasz Skorski, MD, PhD, DSc, 2019  
Temple University  

Karim Tarte, PhD, 2020*  
National Institute of Health and Medical Research  

Enrico Tiacci, MD, 2018  
University of Perugia  

Dr. Enrico Tiacci is funded in part by donations from Edith Klein, the Hairy Cell Leukemia Foundation, and The SASS Foundation for Medical Research, Inc.

Wei Tong, PhD, 2018  
The Children’s Hospital of Philadelphia  

Ashwin Unnikrishnan, PhD, 2020*  
The University of New South Wales  

Dr. Ashwin Unnikrishnan is jointly funded by Snowdome Foundation and Leukaemia Foundation of Australia.

Amit Verma, MD, 2019  
Albert Einstein College of Medicine, Inc.  

Dan Vogl, MD, 2020*  
The Trustees of the University of Pennsylvania, Medical Center  

Dr. Loren Walensky is funded in part by a donation from Liza and James Lafore.

Dr. Loren Walensky is funded in part by a donation from The Holland C. Gregg IV Research Fund.

Kai Wucherpfennig, MD, PhD, 2019  
Dana-Farber Cancer Institute  

Andrew Zannettino, PhD, 2018  
The University of Adelaide  

Fenghuang Zhan, MD, PhD, 2018  
The University of Iowa  

Baocun Zhang, MD, PhD, 2020*  
Dana-Farber Cancer Institute  

Aaron Schimer, MD, PhD, 2020*  
Princess Margaret Cancer Center, University Health Network

Screen to Lead Program  
The Screen to Lead Program offers drug discovery support specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies.

Jolanta Grembecka, PhD, 2020*  
Regents of the University of Michigan  

John Sondek, PhD, 2020*  
The University of North Carolina at Chapel Hill

New Idea Award  
The New Idea Award is a concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related premalignant conditions.

Mark Cobbold, MD, PhD, 2019  
Massachusetts General Hospital

MPN Challenge Grants  
This program is run in partnership with the MPN Research Foundation.

Matyas Ecsedi, MD, PhD, 2020*  
FRED Hutchinson Cancer Research Center

Yelena Ginzburg, MD, 2020*  
ICahn School of Medicine at Mount Sinai

Vikas Gupta, MD, 2020*  
Princess Margaret Cancer Center, University Health Network

Catriona Jamieson, MD, PhD, 2020*  
The Regents of the University of California, San Diego

Alison Moliterno, MD, 2020*  
The Johns Hopkins University School of Medicine

Jyoti Nangalia, PhD, 2020*  
Wellcome Trust Sanger Institute

Vijay Sankaran, MD, PhD, 2020*  
Boston Children’s Hospital

Translational Research Program: Renewal  
Katherine Borden, PhD, 2020*  
Institute for Research in Immunology and Cancer

Leandro Cerchietti, MD, 2019  
Joan & Sanford I. Weil Medical College of Cornell University  

Dr. Leandro Cerchietti is funded in part by a donation from Jane Elissa/Charlotte Meyers Endowment Fund.

Mignon Loh, MD, 2019  
The Regents of the University of California, San Francisco

Feyruz Rassool, PhD, 2019  
University of Maryland at Baltimore

Aaron Schimer, MD, PhD, 2020*  
Princess Margaret Cancer Center, University Health Network

*Newly awarded or renewed grants in Fiscal Year 2020  **Grantee prematurely terminated award in Fiscal Year 2019
IWMF Grants
This program is run in partnership with the International Waldenstrom's Macroglobulinemia Foundation.

Yong Li, PhD, 2020*
Cleveland Clinic Foundation
Constantine Mitsiades, MD, PhD, 2020*
Dana-Farber Cancer Institute
Marcel Spaargaren, PhD, 2020*
Academic Medical Center Amsterdam

Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Prevention Grants for Blood Cancer
This program is run in partnership to advance breakthroughs in the prevention of blood cancers.

C. Ola Landgren, MD, PhD, 2019
Sloan Kettering Institute for Cancer Research

Dr. C. Ola Landgren is funded in part by a donation from Wrobel Family Foundation.

Liran Shlush, MD, PhD, 2019
Weizmann Institute of Science
Dr. Liran Shlush is funded in part by a donation from Wrobel Family Foundation.

George Vassiliou, MD, PhD 2019
Wellcome Trust Sanger Institute
Dr. George Vassiliou is funded in part by a donation from Wrobel Family Foundation.

Mantle Cell Lymphoma Research Initiative
The Mantle Cell Lymphoma Research Initiative supports teams of researchers representing different disciplines and engaging in collaborative efforts to discover new approaches to treat patients with blood cancers.

Selina Chen-Kiang, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University
Dr. Selina Chen-Kiang is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.

Larry Kwak, MD, PhD 2019
Beckman Research Institute of the City of Hope
Dr. Larry Kwak is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.

PedAL
LLS PedAL is a global precision medicine master clinical trial that will test multiple targeted therapies for relapsed acute leukemia simultaneously at up to 200 clinical sites worldwide. We are setting the groundwork for LLS PedAL throughout 2019, with the goal of treating the first patient in the summer of 2020.

Todd Cooper, DO, 2020*
Seattle Children’s Hospital

E. Anders Kolb, MD, 2020*
Nemours Alfred I. duPont Hospital for Children

Samuel Voitenkov, MD, PhD, 2020*
The University of Chicago

Special Initiatives
Peter Adamson, MD, 2019
The Children’s Hospital of Philadelphia
Dr. Peter Adamson is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Carma Bylund, PhD, 2020*
University of Florida
Dr. Carma Bylund is funded in part by a donation from the Carolan Research Institute.

Rena Conti, PhD, 2019
The University of Chicago

Amy Davidoff, PhD, 2020*
Yale University School of Medicine

Stacie Dusetzina, PhD, 2020*
Vanderbilt University Medical Center

Oliver Jonas, PhD, 2020*
Brigham and Women’s Hospital
Dr. Oliver Jonas is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.

E. Anders Kolb, MD, 2019
Nemours Alfred I. duPont Hospital for Children
Dr. E. Anders Kolb is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Soheil Meshinchi, MD, PhD, 2019
Fred Hutchinson Cancer Research Center
Dr. Soheil Meshinchi is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Markus Muschen, MD, PhD, 2020*
Beckman Research Institute of the City of Hope
Dr. Markus Muschen is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.

Susan Parsons, MD, 2020*
Tufts Medical Center

David Teachey, MD, 2019
The Children’s Hospital of Philadelphia
Dr. David Teachey is jointly funded by The Children’s Hospital of Philadelphia.

*Newly awarded or renewed grants in Fiscal Year 2020    **Grantee prematurely terminated award in Fiscal Year 2019
Partnerships

Therapy Acceleration Program Partnerships

Biotechnology Partners
Acetylon Pharmaceuticals, Inc.
Boston, MA
Affimed Therapeutics AG
Heidelberg, Germany
Constellation Pharmaceuticals, Inc.
Cambridge, MA
Decoy Biosciences, Inc.
San Diego, CA
Forty Seven, Inc.
Menlo Park, CA
ImmunGene, Inc.
Camarillo, CA
KDAC Therapeutics, Inc.
Cambridge, MA
Kiadis Pharma NV
Amsterdam, Netherlands
miRagen Therapeutics, Inc.*
Boulder, CO
NexImmune, Inc.
Gaithersburg, MD
OncoPep, Inc.
North Andover, MA
Ryvu Therapeutics SA
Krakow, Poland
Stemline Therapeutics, Inc.
New York, NY
Sutro Biopharma, Inc.
San Francisco, CA
Travera, LLC
Cambridge, MA
Verastem Oncology
Needham, MA
X4 Pharmaceuticals, Inc.**
Cambridge, MA

* Equity investment of $1,000,000 in Fiscal Year 2019
** Equity investment of $3,300,000 in Fiscal Year 2019

Academic Partners
Case Western Reserve University
Cleveland, OH
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, NY
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Oregon Health & Science University
Portland, OR

Advisors

Medical & Scientific Affairs Committee

Steven Rosen, MD, FACP
Beckman Research Institute of the City of Hope Chair
Stephen Ansell, MD, PhD
Mayo Clinic, Rochester
P. Leif Bergsagel, MD
Mayo Clinic, Arizona
Ravi Bhatia, MD
The University of Alabama at Birmingham
Catherine Bollard, MD, MBCB
Children’s Research Institute
S. Lori Brown, PhD, MPH
Former U.S. Food & Drug Administration
Renzo Canetta, MD
Former Bristol-Myers Squibb
Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center
Christopher Flowers, MD
The University of Texas MD Anderson Cancer Center
Janice Gabriole, MD
Icahn School of Medicine at Mount Sinai
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Larry Kwak, MD, PhD
Beckman Research Institute of the City of Hope
Michelle LeBeau, PhD
The University of Chicago
Ross Levine, MD
Sloan Kettering Institute for Cancer Research
Jonathan D. Licht, MD
University of Florida
Ruben Mesa, MD
The University of Texas Health Science Center at San Antonio
Susan M. O’Brien, MD
The Regents of the University of California, Irvine
David Weinstock, MD
Dana-Farber Cancer Institute

Therapy Acceleration Program Committee

Co-Chairs
Dana Callow, MBA
Boston Millennia Partners
C. Casey Cunningham, MD
Santé Ventures

Members
William S. Dalton, MD, PhD1
M2Gen
Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center
Christopher Flowers, MD
The University of Texas MD Anderson Cancer Center
Laura S. Kaufman, PhD, DABT
Private Consultant
Ross L. Levine, MD1
Sloan Kettering Institute for Cancer Research
Ronald Levy, MD
The Board of Trustees of the Leland Stanford Junior University
Vern Norvel, JD
Wilson Sonsini Goodrich & Rosati
Susan M. O’Brien, MD
The Regents of the University of California, Irvine
Robert J. Rosen, JD
Greyhawk Capital Advisors
Steven T. Rosen, MD, FACP
Beckman Research Institute of the City of Hope
David Weinstock, MD2
Dana-Farber Cancer Institute

1 ended service in January 2019
2 started service in January 2019
2019 National Recognition & Awards Program

We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasury and have made a significant difference in the lives of so many. To find out more about our awards program, please go to http://www.LLS.org/national-awards-nomination.

Congratulations to all the 2019 awardees!

President’s Award
This award recognizes a volunteer whose personal commitment and dedication inspires and motivates others to support our mission.
Charles Esten & Family
Tennessee Chapter

Robert de Villiers Spiral of Life Award
This award honors the memory of Robert de Villiers whose parents Rudolph and Antoinette de Villiers founded a foundation that is now known as The Leukemia & Lymphoma Society.
The award recognizes an individual who through their leadership and tireless effort to raise funds and influence policy has advanced the mission of LLS.
Tom Philbrick, MD
Georgia Chapter
Robert (Bob) Dean
Greater Sacramento Area Chapter
Dr. Jerry Adams
Australia

Vision for Life Award
This award recognizes an individual, corporation or organization whose ability to think outside of the box has helped to create a new fundraising campaign/program or has enhanced an existing event that has national potential.
Amanda Tiede
National Capital Area Chapter
Colton’s Army
Washington/Alaska Chapter

Advocacy Award
This award recognizes the commitment and dedication of individuals who support the Office of Public Policy initiatives.
William Teator
Upstate New York/Vermont Chapter

Leadership Award
This award recognizes an individual who has been active in a chapter for at least three years and has provided expertise and guidance that have helped the chapter achieve new levels of success.
Gregg & Karen Ritchie
California Southland Chapter
Scott Jackson
Eastern Pennsylvania Chapter
Bill Rawlings
Georgia Chapter
K.Sue Duncan
Greater Bay Area Chapter
Roland Guillen
Greater Sacramento Area Chapter
Carmen Cruz
Long Island Chapter
Robert and Jenny Kotler
Mississippi/Louisiana Chapter
Tom Davis
North Carolina Chapter
Miller Paint
Oregon SW Washington Idaho Chapter
Ronda Conger
Oregon SW Washington Idaho Montana Chapter
Sam Forrest
Palm Beach/Treasure Coast Chapter
Bryan Austin
Rocky Mountain Chapter
Dr. Scott Kruger
Virginia Chapter
Dr. Richard Hansen
Wisconsin Chapter

Quality of Life Award
This award recognizes a member of the medical community, a social worker, or a caregiver, who has provided outstanding support, counsel or guidance to blood cancer patients or their families.
John M. Timmerman, MD
California Southland Chapter
Neal Rosen
Greater Bay Area Chapter
Dulcy Wilson
Greater Sacramento Area Chapter
Jamie McDonald, LCSW
New Mexico Chapter
Kathryn Kolibaba, MD
Compass Oncology
Dr. Grenita Lathan
Texas Gulf Coast Chapter
Elizabeth Jordan
Texas Gulf Coast Chapter
Howard Hughes Corporation
Texas Gulf Coast Chapter

Special Recognition Award
This award recognizes an individual who is deserving of recognition for their outstanding commitment to an event or program that has resulted in increasing revenue and building public awareness of LLS.
TGI Fridays - The Brad Group
California Southland Chapter
Gregg Metcalf
Georgia Chapter
Caitlin Grace
Greater Bay Area Chapter
Arlette Garcia
Greater Sacramento Area Chapter
David Mutnick
Illinois Chapter
Brenda McCarthy
Long Island Chapter
Marc and Shari Weissbach
Long Island Chapter
Jennifer Oz
Orange County Inland Empire Chapter
I Choose Joy
Oregon SW Washington Idaho Montana Chapter
Katlin Caffman
Oregon SW Washington Idaho Montana Chapter
Paige McCoy
Rocky Mountain Chapter
Ron Cohn
San Diego Chapter
Dr. Grenita Lathan
Texas Gulf Coast Chapter
Elizabeth Jordan
Texas Gulf Coast Chapter

We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasury and have made a significant difference in the lives of so many. To find out more about our awards program, please go to http://www.LLS.org/national-awards-nomination.

Congratulations to all the 2019 awardees!

National Recognition & Awards Recipients

Robert de Villiers Spiral of Life Award
This award honors the memory of Robert de Villiers whose parents Rudolph and Antoinette de Villiers founded a foundation that is now known as The Leukemia & Lymphoma Society.
The award recognizes an individual who through their leadership and tireless effort to raise funds and influence policy has advanced the mission of LLS.
Tom Philbrick, MD
Georgia Chapter
Robert (Bob) Dean
Greater Sacramento Area Chapter
Dr. Jerry Adams
Australia

Vision for Life Award
This award recognizes an individual, corporation or organization whose ability to think outside of the box has helped to create a new fundraising campaign/program or has enhanced an existing event that has national potential.
Amanda Tiede
National Capital Area Chapter
Colton’s Army
Washington/Alaska Chapter

Advocacy Award
This award recognizes the commitment and dedication of individuals who support the Office of Public Policy initiatives.
William Teator
Upstate New York/Vermont Chapter

Leadership Award
This award recognizes an individual who has been active in a chapter for at least three years and has provided expertise and guidance that have helped the chapter achieve new levels of success.
Gregg & Karen Ritchie
California Southland Chapter
Scott Jackson
Eastern Pennsylvania Chapter
Bill Rawlings
Georgia Chapter
K.Sue Duncan
Greater Bay Area Chapter
Roland Guillen
Greater Sacramento Area Chapter
Carmen Cruz
Long Island Chapter
Robert and Jenny Kotler
Mississippi/Louisiana Chapter
Tom Davis
North Carolina Chapter
Miller Paint
Oregon SW Washington Idaho Chapter
Ronda Conger
Oregon SW Washington Idaho Montana Chapter
Sam Forrest
Palm Beach/Treasure Coast Chapter
Bryan Austin
Rocky Mountain Chapter
Dr. Scott Kruger
Virginia Chapter
Dr. Richard Hansen
Wisconsin Chapter

Quality of Life Award
This award recognizes a member of the medical community, a social worker, or a caregiver, who has provided outstanding support, counsel or guidance to blood cancer patients or their families.
John M. Timmerman, MD
California Southland Chapter
Neal Rosen
Greater Bay Area Chapter
Dulcy Wilson
Greater Sacramento Area Chapter
Jamie McDonald, LCSW
New Mexico Chapter
Kathryn Kolibaba, MD
Compass Oncology
Dr. Grenita Lathan
Texas Gulf Coast Chapter
Elizabeth Jordan
Texas Gulf Coast Chapter
Howard Hughes Corporation
Texas Gulf Coast Chapter

Special Recognition Award
This award recognizes an individual who is deserving of recognition for their outstanding commitment to an event or program that has resulted in increasing revenue and building public awareness of LLS.
TGI Fridays - The Brad Group
California Southland Chapter
Gregg Metcalf
Georgia Chapter
Caitlin Grace
Greater Bay Area Chapter
Arlette Garcia
Greater Sacramento Area Chapter
David Mutnick
Illinois Chapter
Brenda McCarthy
Long Island Chapter
Marc and Shari Weissbach
Long Island Chapter
Jennifer Oz
Orange County Inland Empire Chapter
I Choose Joy
Oregon SW Washington Idaho Montana Chapter
Katlin Caffman
Oregon SW Washington Idaho Montana Chapter
Paige McCoy
Rocky Mountain Chapter
Ron Cohn
San Diego Chapter
Dr. Grenita Lathan
Texas Gulf Coast Chapter
Elizabeth Jordan
Texas Gulf Coast Chapter
Howard Hughes Corporation
Texas Gulf Coast Chapter
Media Awards Recipients

Recipients have a record of excellence in fundraising and promotional support, as well as educating and informing the public of LLS and its mission.

Digital Media

Clear Channel Outdoor
Minnesota Chapter
Brew Creative Media
Minnesota Chapter

Print Journalism

Comstock’s Magazine
Greater Sacramento Area Chapter
The Modesto Bee
Greater Sacramento Area Chapter
Cancer Wellness Magazine
Illinois Chapter
Chris Ohmer
Cincinnati Magazine
Tri-State Southern Ohio Chapter
Cincinnati Magazine
Tri-State Southern Ohio Chapter

Radio

Nick McIlwain
Preston & Steve Show
Eastern Pennsylvania Chapter
WMMR 93.3
Preston & Steve Show
Eastern Pennsylvania Chapter
Hubbard Radio
Gateway Chapter
Cumulus Radio Station
Group I Minneapolis
Minnesota Chapter
Hubbard Radio
WIRK, WRMF
Palm Beach/Treasure Coast Chapter
Melanie Rutledge
KOOL 105
Rocky Mountain Chapter
KOOL 105
Rocky Mountain Chapter
104.5 The Zone
Tennessee Chapter
Sunny 99.1
Texas Gulf Coast Chapter
iHeartMedia - Seattle
Washington/Alaska Chapter

Television

KMOV St. Louis
Gateway Chapter
Toni Valliere
KCRA 3
Greater Sacramento
Area Chapter
KCRA 3
Greater Sacramento
Area Chapter
Good Day Sacramento
KMAX
Greater Sacramento
Area Chapter
WGN-TV
Illinois Chapter
FOX 9 KMSP
Minnesota Chapter
KFYR-TV
Minnesota Chapter
Clay Loney
FOX 23-TV
Tulsa, OK
Oklahoma Chapter
FOX 23-TV
Tulsa, OK
Oklahoma Chapter
Ernie Zuniga
KABB Fox 29
South-Central Texas Chapter
KABB Fox 29
South-Central Texas Chapter

Special Recognition

John Occhipinti
Oklahoma Chapter

Dr. William Dameshek Award

This award honors the memory of Dr. William Dameshek who was a pioneer in developing chemotherapy protocols and who founded the core hematology journal Blood and served as its editor for many, many years.

This award recognizes nationally recognized notables and celebrities who have lent their voice and image to advance the LLS mission.

The Beach Boys
Oklahoma Chapter
John Stamos
Oklahoma Chapter
Dana Tyson
Texas Gulf Coast Chapter
We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

**Leadership Circle**  
$500,000-$999,999
- AbbVie, Inc.  
- Amgen, Inc.  
- Astellas Pharma U.S., Inc.  
- Bloomberg Philanthropies  
- Carolan Research Institute*  
- Don & Lorraine Freeberg Foundation  
- Kite, A Gilead Company  
- Lang / Stiglitz Family Fund  
- Katherine and James Lau*  
- Leukemia Foundation*  
- MUY Hamburger Partners LLC  
- The Norcross Foundation, Inc. In Memory of Herrick F. Norcross, Jr. (Rick)*  
- Novartis Pharmaceuticals  
- Lynne and Greg O’Brien*  
- Salesforce  
- Snowdome Foundation*  
- Toni and Emmet Stephenson*  

**Innovation Circle**  
$250,000-$499,999
- AstraZeneca Pharmaceuticals  
- Atrium Health Foundation*  
- Bristol-Myers Squibb  
- The Charles T. Bauer Charitable Foundation  
- Charles Esten*  
- Global Franchise Group, LLC - Great American Cookies®, Hot Dog on a Stick®, Marble Slab Creamery®, MaggieMoo’s Ice Cream & Treatery®, PretzelMaker®, and Round Table Pizza®  
- Green Tie Gala/Chuck Cuda  
- GSP Transportation, Inc.  
- Jersey Mike’s Subs  
- Kenneth & Verna Mae Jessen Trust  
- The Orokawa Foundation, Inc.  
- Pfizer, Inc.*  
- Shoot For A Cure  
- Stater Bros. Markets  
- Mona Carlton Stogner and Grey Stogner*  
- Anonymous (1 donor)  

**President’s Circle**  
$1,000,000 and Above
- Monica and Timothy Babich*  
- Jeff Binder  
- Burlington  
- Celgene Corporation  
- Cynthia and Frank Gasztonyi*  
- Dr. Ralph & Marian Falk Medical Research Trust*  
- Genentech/Biogen  
- Gilead Sciences, Inc.  
- The Harry T. Mangurian Jr. Foundation, Inc.*  
- Jazz Pharmaceuticals, Inc.*  
- LIUNA Charitable Foundation*  
- The Lyon Family Foundation*  
- Pharmacyclics/Janssen  
- Donald Porteous*  
- Joan and Paul Rubschlager*  
- The Sarah Cannon Fund at the HCA Foundation*  
- Schwartz Ward Foundation*  
- Subaru of America Inc.  
- Takeda Oncology  
- UFCW  
- Walgreens  
- The Wawa Foundation  
- Anonymous (1 donor)  

**Leadership Circle**  
$100,000-$249,000
- Albert & Elia Borchard Foundation  
- The Alice Lawrence Foundation  
- Alto-Shaam, Inc.  
- Anna and Dean Backer*  
- John and Nonnie Barbey  
- Black Dog Charity  
- Bloomberg  
- William and Tamea Bock  
- The Boldt Family Philanthropy Fund*  
- BR Purchasing  
- Janice and Peter Brock*  
- S. Lori Brown  
- Cal Turner Family Foundation*  
- Celebrity Cruises  
- The Charles Engelhard Foundation*  
- Lisa Norcia Cheskin and Barry Cheskin*  
- The Chicago Community Foundation  
- Cleveland Clinic  
- Michael and Liz Copley*  
- Custom Ink  
- Daiichi Sankyo  
- Robert and Cindy Dickinson  
- John and Ann Doerr  
- Earl D. and Marian N. Olson Fund  
- The Edward J. Phillips Family Foundation*  
- Enmark Stations, Inc.  
- F. M. Kirby Foundation, Inc.  
- Chiyoko Furukawa*  
- Greater Milwaukee Foundation, Inc.*  
- The Hairy Cell Leukemia Foundation*  
- The Hearst Foundation  
- Higgins Family Charitable Foundation  
- Incyte Corporation  
- The J.T. Tai & Co. Foundation, Inc.  
- William and Jennifer Kenneally*  
- The Laborers Charitable Foundation  
- Joyce and Larry Lacerte*  
- Paul Leinwand  
- Jeanne and Steve Lieblich*  
- Cristine and Timothy Lindenfelser  
- Mable Hamann Revocable Trust  
- Clyde McGregor and LeeAnn Pederson Pope  
- Melissa Reasner McGuire Advised Endowment Fund  
- Memorial Cancer Institute  
- Melovee White Trust Alice L Clare Trustee  
- Nike, Inc.  
- NSC Global  
- Rick Ostroff*  
- Pennsylvania Department of Health  
- Presidio  
- PSEG Foundation  
- PWC  
- Rahr Corporation*  
- Pat and Jeff Sachs*  
- The SASS Foundation for Medical Research, Inc.*  
- Jeff Schoepfel  
- Michael Scotece  
- Silicon Valley Bank  
- Stanford Children’s Health  
- Stifel  
- Sylvester Comprehensive Cancer Center, University of Miami  
- Teva Pharmaceuticals  
- Gary and Angela Trovato*  
- TrueNorth Energy  
- UCLA Health  
- VyStar Credit Union  
- West Marine  
- Wrobel Family Foundation  
- Roger Zacher  
- Anonymous (4 donors)
Ice Mobility Foundation

IBERIABANK

John and Kristin Hyland

HM Insurance Group

Foundation Inc.

Hildegarde D. Becher

Heritage Title

Marianne Heatherly

The Hatton Foundation

Dan Harrington

Lead Trust

Harold Salmanowitz Charitable

Hannig Law

Krispy Krunchy Foods, LLC

L & R Structural Corp.

KPMG

Lighthouse Partner

Judith and Charlie Lynch*

Maine Cancer Foundation

Joe Maio

McKesson Specialty Health

Medicare Properties Trust

Corrine and Jon Merksamer*

Miami Cancer Institute

Mikuni Charitable Organization

Montgall Scholarship Fund, Inc.

The Moorings

Nancy Nasher and David

Hamesseger

The Nashville Wine Auction

Chris Neibauer

Nimick Forbesway Foundation

Norwegian Cruise Line

Lindsey Noto

Opral Wealth Advisors

Ostroff Associates

Kaylene and Rajiv Patel

Pieper Electric, Inc.

The Ping Y. Tai Foundation, Inc.

PinkTie.org

Pizza Hut of America, Inc.

Planned Systems International

PNC Bank

Fred and Cherie Pond*

PRA Health Sciences

Dr. George Rapier

Barbara and Brent Reid

Robert E. Gallagher Charitable Trust

Melody and Rick Rogers

Lois and Jerry Rosenblum

Sagepoint Financial, Inc.

Stacy Sager

SagerStrong Foundation Inc.

SAIC

Salt River Pima-Maricopa Indian

Community (SRPMIC)

Neil Salvage

Sarver Charitable Trust

Seattle Genetics ☎️

Sempra Energy

Mr. and Mrs. Richard Smith

Snap Crack Chiropractic

Margaret and Donald Steiner

SummitIIG

Survivor Spotlight

Mark Taylor

Thrivent Choice Wisconsin

United Way of San Antonio and

Bexar County

Verizon

VGM Associates Ltd.

The Victor E. & Caroline E.

Schutte Foundation

The Walt Disney Company

The Ward Law Group

Wells Fargo

Wendmille LLC

West Pharmaceutical

Services, Inc. ☎️

Wilhelm Restaurant Group, Inc.

Anonymous (2 donors)
Cool Springs Financial
Coro and John H. Davis Foundation
Costco Charitable
Kevin Coxon
Cruise Planners
Dana Farber Cancer Institute
The Danaher Foundation
Dayton Children’s Hospital
Dealer Tire
Michael Del Giudice
Delaware Community Blood Foundation, Inc.
Desert States Charitable Foundation
Dickinson Fleet Services LLC
Dan Diepenhorst
Digital Federal Credit Union
Dignity Health
Dominion Energy
Domtar
Don C. and Diane S. Lake Family
Don Miller Subaru East
Don Miller Subaru West
Donnelley Financial
Marian Dozier
Edith M. Schweckendieck Trusts
Edward G. & Kathryn E. Mader Foundation
Edward Jones
EFESTÉ
Eli Lilly and Company
Emerson Charitable Trust
EMI Research Solutions
ePLUS Technology, Inc.
Erie Insurance
Mr. Ed Ewing
EY
The Fama Family Charitable Fund
The Fernandez Foundation, Inc.
Fieter Family Fund
Fight Like Hell Golf JAM
The Firstenburg Foundation
Florentine Camenisch Foundation
Florida Power & Light
FMC Corporation
Forward Advantage Foundation Inc.
Foundation Medicine
Friends of Las Vegas Metropolitan Police Foundation
Furniture Fair
Mr. and Mrs. Chris Gallagher
Gallo Family Charitable Fund
Garber Automotive Group
Jeanne Gardner
GDIT
General Dynamics
Genesee Mountain Foundation
Genentech
Global Atlantic Financial Group
Grant Thornton LLP
H. Lee Moffitt Cancer Center & Research Institute
HAC, Inc.
Nancy Hamlin
Hargrove Foundation
John Harrison
Healthcare Management Administrators
HealthEquity
Heartland Blood Centers
HEB
Alice Hejl
Kathleen and Mark Helge
Hendrick Family Foundation
Heroes Inc.
Highmark Blue Cross Blue Shield and Allegheny Health Network
Hogan-Rutherford Inaugural Committee
The Howard Hughes Corporation
Huntsman International LLC
IBC Bank
Infor Global Solutions
Intermountain Healthcare
J.P. Morgan Charitable Giving Fund
Jane and David Jackson
Michael and Jane Jamieson
JE Dunn Construction
Jerome S. and Grace H. Murray Foundation
The Jim Jacobs Foundation
Jochum-Moll Foundation
The John G. Rangos Sr. Charitable Foundation
The Joseph and Catherine Johnson Family Foundation
Josephine Johnson
Kaiser Permanente
Karyopharm Therapeutics
Kendra Scott
Tai-Yee Kiang
Kilroy Realty Corporation
Peter and Laura Klekamp
Gerry and Penney Klingman
LDC Health & Safety
The Lipstein Family
Lockton Companies
Lodging Hospitality Management Corporation
Luck Stone Corporation
Lunardi’s Markets
The Luppe and Paula Luppen Family Foundation
Luther White Bear Subaru
M&T Bank
M&T Bank/Wilmington Trust
M.G. O’Neil Foundation
Marcus and Millichap
The Marcus Foundation, Inc.
Lois Markovich
Paula and Larry Marshall
Mason City School District
Massapequa Turkey Trot
Mr. and Mrs. Bryan Mattson
MAXIMUS
Mays Family Foundation
McCaffrey Interests Inc.
Drew and Shelley McCandless
The McCarthy Family
McKenney’s, Inc.
Melnyder Foundation*
Memorial Healthcare System
Memorial Sloan-Kettering Cancer Center
Daniel Mendez
Merck & Company
Steve and Ellen Miura
Mercury
MKJ Communications
Steve and Ellen Miura
MKJ Communications
Monumental Sports & Entertainment Foundation
Robert Moore
Morguard
MSS
Susan Munzer
James Murray
Names Family Foundation
New Signature
The North Bay Cancer Alliance*
Northside Hospital
Ochsner Health System
OH&J Jewish Hospital – Mercy Health
The Order of St. Benedict of New Jersey
Oregon Oncology Specialists
Orlando Health UF Health Cancer Center
Otsuka
P.Y. Pancakes, INC. DBA / IHOP #678
Passion Planner LLC
Penn Medicine
Pepsi
Perfumania
Sonja and Jon Perkins
Tracy Peters
Scott Peyree
PFG/Vistar
Drs. Bud and Selma Pierce
Pray Family Foundation
Protiviti
Prudential Financial
PurePoint Financial
Rambus
Rathgeber Investment GP Inc.
RCCA
Lisa and Robert Reeves
REMAX Gateway
Rheingold Family
Jason Richmond
Richmond County Savings Foundation
Riemer & Braunstein LLP
Steve Rigby
William and Lynne Rogers
ROMA Charitable Foundation
Robert and Nancy Rosen
Steve Rosen
RPM Pizza (Domino’s Pizza)
Daniel and Susan Ryan
Samlyn Capital LLC
Sanofi Genzyme
Save the Fox Foundation
Arlene Schafer
Drew and Donna Schwartz
The Sessions Firm
The Sevan Charitable Foundation, Inc.
Irene and Fred Shabel
Faisal Shaikh
The Shapiro Family Foundation
Sharp 594, Inc. DBA / IHOP 594
Shumaker, Loop & Kendrick, LLP
Floyd and Noreen Singleton
Sinkula Investments, LTD
Skanska
The Skynyrd Foundation
SoCalGas Turkey Shoot
Southern Glazer’s Wine & Spirits
Ryan Spain
Special Kids Network, Inc.
St. Joseph’s/Candler
Stand Together Music Festival
Strike
Sturgeon Electric
SunTrust
SuperValu Inc.
Sutter Health
Suvoda
Michael Sweig
Target CW
TECO Energy
Terumo BCT
Texas Instruments, Inc.
Thunderbirds Charities
Tigerfight Foundation
Tilden-Coil Constructors Team KSmo
Todd Reed McClintock Research Foundation
Tolero Pharmaceuticals, Inc.
C
Tour de Court 2019
Travel Leaders Group
Trevor Loughlin Foundation Inc.
True North Studio
Ultimate Software
UNC REX Healthcare
United Way of Greater Milwaukee & Waukesha County, Inc.
UnitedHealthcare
The University of Kansas Cancer Center
University of Michigan Rogel Cancer Center
The University of Texas MD Anderson Cancer Center
UPMC
Valero
Valley Children's Hospital
Larinda Van Groningen
VCU Health System
Venable LLP
Judith Von Seldeneck
Wafra Inc.
Washington Gas Light Federal Credit Union
Greg Weimer
Ellen Weissberg
Gloria Weissberg
Mark Weissberg
Wellmed Charitable Foundation
Wespac Construction Inc.
Wet Willie’s Management Corp.
William R. Rich Foundation
James and Judy Wilson
WiSC Enterprises
Anonymous (5 donors)

$10,000-$24,999
101 Surf Sports
43rd Annual Amusement Theme Park Conference
60Feet6 Foundation
Abacus Technical Services, LLC
The Abatecola Foundation
Bruce Abbey
Sandy Abbott
Linda and Tim Abell
Accel
Accelerated Urgent Care
Access Capital Foundation
Accord Healthcare, Inc.
ACE Family Foundation
Acertitude
Ann Adams
Susan Adams
Michael Adams
Adaptive Biotechnologies
Adonel Concrete
Advance Auto Parts
Advanced Computer Concepts
Aerotek
Aetna
Allc
Against the Storm Foundation
Greg Ager and Dave Dolan
AIG
Alaska Airlines Matching Program
Michael and Melissa Alber
The Albrecht family
Alexandria Real Estate Equities, Inc.
Alibaba Group
Allegion
Adam Allen
Pat and Debbie Allender
Alliance RX Walgreens Prime
Alliant Insurance Services
Allied Associates International
Allmond & Company, LLC
Amadeus North America, Inc.
AmCap Mortgage, LTD
Amerant Bank
American Ambulance
American Punjabi Charity
Golf Association
AMERICAN SYSTEMS
Ames Construction
Ami Onco Theranostics
Anadarko
Anaheim Ducks Foundation, Inc.
Dwight Anderson
Jean and C.E. Andrews
Anne Wilson
ANRAK Corporation
Ansira
Anthem
Anthem Blue Cross
AON Corporation
Aon Risk Services
Apex Foundation
Apple
Arizona Public Service
APTO Solutions
Aptose Biosciences
Margaret Arakawa
Arch-Con Corporation
Steve Armstrong
Phillip Armstrong
Arnof Kearns Family Foundation
Donor Advised Fund
Ascend Learning LLC
Ascension
Associated Credit Union
Assurant
Astellas
Asuragen, Inc.
The Atlanta Foundation
Atlantic Health System
Austin Hardware & Supply
Authentic
Avalere Health
AvalonBay Communities, Inc.
Avantor Sciences Foundation
Aventri
Avery
Avision Young USA Inc.
Baker Botts
Baker Hughes Foundation
Baltimore Orioles
BankSouth Mortgage
Banner MD Anderson
The Bar LV
The Barbara and William Rosenthal Family Foundation
Dr. and Mrs. William Barfield
Maggy Barnaba
George Barr
Karl Barron
Adel Barry
Bartlett Cocke General Contractors
Michael Bartschat
Bath Fitter
Batteries Plus Bulbs
BayCare
Diane Baylor
BB&T
BBG of NKY
BCM One, Inc.
Be A Man Buy Land
Mr. Edmund Beebe
Beitway Cleaning Services
Bender Foundation, Inc.
Bender Insurance Solutions
Christopher Benrud
Michele and Howard Berger
The Bernal T. Chomeau Private Foundation
Bernard J and Camille Cebelak Foundation
Bernhard MCC
Paula Berry
Beta Engineering California LP
Laura and Steve Beuerlein
Deep Bharadwaj
B1 Worldwide
Bill Thomas Associates, Inc.
Lisa Bilotti Foundation
Biotechnology Innovation Organization
Bird Road Subaru
George Bishop
BJ’s Restaurant Foundation, Inc.
Seth & Stacy Blackman Charitable Fund
Connie Blackmon
Alien Blakemore
Angela Blank
Bloodworks NW
Blue Cross Blue Shield of Kansas City
Blue Marble Cocktails
Blue Water Financial Partners
Meredith Bluhm Wolf
BMC
Bob Rohrman Lexus of Arlington
Nancy Boeck
Alex Boggs
Janet and Logan Boggs
Boies Schiller & Flexner
Kelli and Don Bonacci
Nicole Bond
Bootleggers’ Bash
Booz Allen Hamilton
Kate and David Borowski
Boston Biomedical
Boston Consulting Group
Boston Properties
Boston’s Best Coffee Roasters
Pike Electric
PJW, LLC
Planet Fitness
Platformq, Health, Inc.
Eileen and Gerald Poblocki
Kim and Nick Pomponi
Pondurance LLC
Scott Poole
Porsche North Scottsdale
Porsche of New Orleans
Porter Hedges LLP
Portland General Electric
Powell Industries
Praxair
Precision Biosciences, Inc.
Precision Lender
Press Ganey Associates
Mr. and Mrs. Jeff Preston
Mr. and Mrs. John W. Preston
Prometheus Partners
The Puente Family
Charline Pulizzi
Pure Storage
Quest Diagnostics
Quicken Loans
Quorum Software
R. G. Miller Engineers
The Rabbitt Whalen Family Foundation
Elizabeth Raleigh
Barbara Rapaport
Raymond James
Dorine Real and Lee Tepper
Real Estate One Foundation
Ms. Kimberly Reckley
RED Capital Group
Red River Technology
Jason and Heather Redpath
Regal Foundation
Regatta Network
The Reinalt-Thomas Corporation
Randy and Debbie Rehmann
Andrea Reid
Adam Reinhardt
Mr. and Mrs. David Rendina
Mrs. Marjorie Rendina
Mr. and Mrs. Richard Rendina
Resilience Capital Partners
The Rhoda and David Chase Family Foundation, Inc.
Polly and Gregg Ribatt
Joe Ricciuti
Mr. and Mrs. Troy Rice
Richard M. Schulze Family Foundation
Rifenburg Construction
RMD Investors
Steve Robert
Robert J. Healy Elementary
The Robert R. Sprague Foundation
The Roberts Family
Roberts Oxygen Company, Inc.
Doug Robinson
Mr. and Mrs. John W. Robinson III
Gene Rochlin
Rock the Campus
Rockefeller Foundation
Rockland’s Greatest LTD
Rock Mountain Cancer Centers
The Roderick Sward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.
Bonnie and Sam Roditti
Rotary Club of Nashua West
Rottendorf Pharma, Inc. ☺
Mary Rowan
RSI
Keith Russell
Roger Russell
Ruth Robinson
Jason Ryan
David Ryle
Robert & Barbara Sablowsky Foundation
Jeffrey and Catherine Sachs
SafeWays
The SafeWays Foundation
SailPoint Technologies
Salinas Valley Memorial Healthcare System
Niki Salter
Salzmann Hughes, P.C.
Sam J. Frankino Foundation
Sam’s Club
The Samek Law Firm
San Diego Sign Company
The San Francisco Foundation
San Jose Earthquakes
SAP Concur
SAP NS2
Sarah Tarditi Gallagher Memorial Golf Outing
John Saunders
Mr. and Mrs. Mark Saur
Savannah Chatham Imaging
Sawnee Electric Membership Foundation Inc.
Joel and Natalia Saxton
Anthony Scaramucci
The Schaeufelin Family Foundation
Scheid Family Wines
Laura Schlegel
Brian and Sandra Schneider
Schnucks Markets, Inc.
Schorr-Liebermann Family Foundation
Schumacher Construction Management, Inc.
Charles Schwab
Robert and Jennifer Schwing
Helena Scott
Scotts Valley High School
Scripps Green Hospital
SDS Restaurant Group LLC
The Segerstrom Foundation
Paul Seipp
Mark Seltzer
Servier Pharmaceuticals ☺
Carl Sewell
Sewell Automotive Company
Seyfarth Shaw LLP
Samuel Shaheen
C. Kevin Shannahan
Sharp 471, Inc. dba / IHOP 471
John Shaw
Bill and Diane Shaw
Jere Shawver
Shepherd’s Chevrolet Buick GMC
Sherwood Forest SC
Douglas and Barbara Shindler
Matthew Shirah
Kevin Shivers
John and Marcia Shooshan
Shopprright Supermarket of Cherry Hill Inc.
R.L. Sias
Bart and Linda Sichel
Sidley Austin LLP
The Sidney, Milton and Leoma Simon Foundation
Sidney Kimmel Cancer Center at Thomas Jefferson University
Michael Siegel
Silicon Valley Community Foundation
Silver State Schools Credit Union
Mr. and Mrs. Robert Simmons
Simpson Food Group
Neal Simpson
Simpson Thacher
Dwight Sippelle
Sirius
Site Master
Skoda Contracting Co., Inc.
Charles and Meg Slater
The Sleep Family
Brad Smith
Douglas and Phyllis Smith
E. Smith
Jeff and Marnie Smith
Kristie Smith
Lester Smith
Mack Smith
Michael Smith
Michael L. Smith
William Smith
Hermine Soler
Sonic Automotive
Southeastern, Inc.
Southgate Glass
Southwest Local School District
Bonnie and Stephen Spiegle
Spire, Inc.
H. Mark Spenseller
Springfield Pancakes, Inc.
IHOP #4509
St. David’s Healthcare
St. Juste Management Corp.
Robert Stall
Gretchen Stanger
Star Anesthesia, PA
Statewide Restoration
Barb and Tom Stayton
Steel Dynamics Inc. & Keith Busse
Enterprises
Kevin K. Steiner
Stemline Therapeutics
Jon Sterling
Jeffrey Stern
Steward Family Foundation
Strifel Financial
Mr. Kenny Stiles
Stritza
Stoller Family Foundation
David Stone and Aileen Karstofsky
Kristin Stork
Strategic Education, Inc.
Strategic Site Development, LLC
<table>
<thead>
<tr>
<th>Company/Individual</th>
<th>Contributions</th>
</tr>
</thead>
<tbody>
<tr>
<td>TomTom North America</td>
<td>$25,000</td>
</tr>
<tr>
<td>Family Foundation, Inc.</td>
<td>$25,000</td>
</tr>
<tr>
<td>Tom &amp; Virginia Jennaro</td>
<td>$20,000</td>
</tr>
<tr>
<td>Tolero Pharmaceuticals</td>
<td>$20,000</td>
</tr>
<tr>
<td>T-Mobile</td>
<td>$20,000</td>
</tr>
<tr>
<td>TKTMJ, Inc.</td>
<td>$20,000</td>
</tr>
<tr>
<td>TJX Foundation, Inc.</td>
<td>$20,000</td>
</tr>
<tr>
<td>Joshua Titus</td>
<td>$20,000</td>
</tr>
<tr>
<td>Tito's Handmade Vodka</td>
<td>$20,000</td>
</tr>
<tr>
<td>Thornton Tomasetti, Inc.</td>
<td>$20,000</td>
</tr>
<tr>
<td>Thompson Habib and Denison</td>
<td>$20,000</td>
</tr>
<tr>
<td>Thomas and Agnes Carvel Consulting Group</td>
<td>$20,000</td>
</tr>
<tr>
<td>Sub Pop Records</td>
<td>$15,000</td>
</tr>
<tr>
<td>Suez Water Technologies and Solutions</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tim Sullivan</td>
<td>$15,000</td>
</tr>
<tr>
<td>Sullivan &amp; Cromwell LLP</td>
<td>$15,000</td>
</tr>
<tr>
<td>Summit State Bank</td>
<td>$15,000</td>
</tr>
<tr>
<td>Superior Subaru</td>
<td>$15,000</td>
</tr>
<tr>
<td>Supermarket of Cherry Hill</td>
<td>$15,000</td>
</tr>
<tr>
<td>Steven Suttle</td>
<td>$15,000</td>
</tr>
<tr>
<td>Andrew Sveikauskas</td>
<td>$15,000</td>
</tr>
<tr>
<td>Mr. and Mrs. Jack Swan</td>
<td>$15,000</td>
</tr>
<tr>
<td>Mr. and Mrs. Rob Swan</td>
<td>$15,000</td>
</tr>
<tr>
<td>Swedish Cancer Institute</td>
<td>$15,000</td>
</tr>
<tr>
<td>Sykes Enterprises</td>
<td>$15,000</td>
</tr>
<tr>
<td>Symancor Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>SYNNEX Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Sysco Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Bettyann Szotak</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tampa Bay Buccaneers &amp; Manchester United F.C.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tampa Bay Lightning</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tampa Bay Rays Baseball</td>
<td>$15,000</td>
</tr>
<tr>
<td>Ann Taylor</td>
<td>$15,000</td>
</tr>
<tr>
<td>TD Bank</td>
<td>$15,000</td>
</tr>
<tr>
<td>Team Kirsten</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tee It Up to Cure Leukemia – Jana &amp; Warren Brickey</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tellabs</td>
<td>$15,000</td>
</tr>
<tr>
<td>Terakeet LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>Terry D. and Carol A. Agness Charitable Trust</td>
<td>$15,000</td>
</tr>
<tr>
<td>Texas AirSystems LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>Texas Oncology</td>
<td>$15,000</td>
</tr>
<tr>
<td>Terri Theisen</td>
<td>$15,000</td>
</tr>
<tr>
<td>TheHouse.Org</td>
<td>$15,000</td>
</tr>
<tr>
<td>Thiesen Dueker Financial Consulting Group</td>
<td>$15,000</td>
</tr>
<tr>
<td>Thomas and Agnes Carvel Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Thompson Habib and Denison Thornton Tomasetti, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tito's Handmade Vodka</td>
<td>$15,000</td>
</tr>
<tr>
<td>Joshua Titus</td>
<td>$15,000</td>
</tr>
<tr>
<td>TJX Foundation, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>TKTMJ, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>T-Mobile</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tolero Pharmaceuticals</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tom &amp; Virginia Jennaro Family Foundation, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>TomTom North America</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tooley Oil Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Jay Torborg and Diana Dickinson</td>
<td>$15,000</td>
</tr>
<tr>
<td>Toyota</td>
<td>$15,000</td>
</tr>
<tr>
<td>Trademark Title</td>
<td>$15,000</td>
</tr>
<tr>
<td>Transwestern</td>
<td>$15,000</td>
</tr>
<tr>
<td>Travel Resorts of North Carolina, LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>Kari and Greg Trayer</td>
<td>$15,000</td>
</tr>
<tr>
<td>Treen Events</td>
<td>$15,000</td>
</tr>
<tr>
<td>Trent &amp; Teresa Jackson Family Fund</td>
<td>$15,000</td>
</tr>
<tr>
<td>Triangle Oktoberfest Rotary Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>TruHealth</td>
<td>$15,000</td>
</tr>
<tr>
<td>Trust Company of the South</td>
<td>$15,000</td>
</tr>
<tr>
<td>Eddy Tsang</td>
<td>$15,000</td>
</tr>
<tr>
<td>Albert Tsui</td>
<td>$15,000</td>
</tr>
<tr>
<td>Tulliet Prebon Americas Holding</td>
<td>$15,000</td>
</tr>
<tr>
<td>Jill Turner</td>
<td>$15,000</td>
</tr>
<tr>
<td>Turner Construction Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>William Tutwiler</td>
<td>$15,000</td>
</tr>
<tr>
<td>Barbara Tyson</td>
<td>$15,000</td>
</tr>
<tr>
<td>U.S. Chamber Of Commerce Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>UAW Medicine</td>
<td>$15,000</td>
</tr>
<tr>
<td>UAW Ford Flat Rock Assembly Plant</td>
<td>$15,000</td>
</tr>
<tr>
<td>UBS Financial Services Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>UCLA President’s Fund</td>
<td>$15,000</td>
</tr>
<tr>
<td>UK HEALTHCARE</td>
<td>$15,000</td>
</tr>
<tr>
<td>Unanet</td>
<td>$15,000</td>
</tr>
<tr>
<td>United Capital</td>
<td>$15,000</td>
</tr>
<tr>
<td>United States Marine, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>United Therapeutics Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Universal Electric Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital</td>
<td>$15,000</td>
</tr>
<tr>
<td>The University of Chicago</td>
<td>$15,000</td>
</tr>
<tr>
<td>University of Southern California Upchurch Kimbrough, LTD.</td>
<td>$15,000</td>
</tr>
<tr>
<td>US Bank</td>
<td>$15,000</td>
</tr>
<tr>
<td>UTSW Simmons Cancer Center VAE</td>
<td>$15,000</td>
</tr>
<tr>
<td>Natan and Beth Vaisman</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Valente Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Valley Electric</td>
<td>$15,000</td>
</tr>
<tr>
<td>Value Pay Services</td>
<td>$15,000</td>
</tr>
<tr>
<td>Deanna Van Gestel</td>
<td>$15,000</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Vanguard Charitable Fund VCC, LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>Julie and Phil Venables</td>
<td>$15,000</td>
</tr>
<tr>
<td>Philip Venables</td>
<td>$15,000</td>
</tr>
<tr>
<td>Verastem</td>
<td>$15,000</td>
</tr>
<tr>
<td>Versiti, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Lea Vickery</td>
<td>$15,000</td>
</tr>
<tr>
<td>Vida Global Foundation, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Virginia Friedhofer Charitable Trust</td>
<td>$15,000</td>
</tr>
<tr>
<td>Virginia Sheldon Jerome (VSJ) Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Vita Coco</td>
<td>$15,000</td>
</tr>
<tr>
<td>Carol and Thomas Voss</td>
<td>$15,000</td>
</tr>
<tr>
<td>The W. O’Neil Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Christian and Lina Waage</td>
<td>$15,000</td>
</tr>
<tr>
<td>Wall Family Enterprises, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Wallace Fox Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Walmart</td>
<td>$15,000</td>
</tr>
<tr>
<td>Walter Johnson High School</td>
<td>$15,000</td>
</tr>
<tr>
<td>Julianne Ward</td>
<td>$15,000</td>
</tr>
<tr>
<td>WARNERMEDIA</td>
<td>$15,000</td>
</tr>
<tr>
<td>Washingtonian Magazine</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Washington Redskins</td>
<td>$15,000</td>
</tr>
<tr>
<td>Waste Connections, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Water Utility Management Company, LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>WB Engineers+Consultants</td>
<td>$15,000</td>
</tr>
<tr>
<td>Maureen and Doug Webster</td>
<td>$15,000</td>
</tr>
<tr>
<td>Well Cornell Medical College</td>
<td>$15,000</td>
</tr>
<tr>
<td>David Weinstein</td>
<td>$15,000</td>
</tr>
<tr>
<td>Robert Weismantel</td>
<td>$15,000</td>
</tr>
<tr>
<td>David Welland</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Wellmark Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Werther Family</td>
<td>$15,000</td>
</tr>
<tr>
<td>Western &amp; Southern Life</td>
<td>$15,000</td>
</tr>
<tr>
<td>Western Digital Corporation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Western States Council Leukemia Fund</td>
<td>$15,000</td>
</tr>
<tr>
<td>Whirley-Drink Works</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Whiting-Turner Contracting Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Todd Wigfield</td>
<td>$15,000</td>
</tr>
<tr>
<td>Sherry and John Mark Wilhte Wilco</td>
<td>$15,000</td>
</tr>
<tr>
<td>William and Margaret Schreiber Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Willamette Valley Bank</td>
<td>$15,000</td>
</tr>
<tr>
<td>Douglas Williams</td>
<td>$15,000</td>
</tr>
<tr>
<td>Thomas Williams</td>
<td>$15,000</td>
</tr>
<tr>
<td>Williams Realty &amp; Building Company, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>Patricia Willson</td>
<td>$15,000</td>
</tr>
<tr>
<td>WilmerHale</td>
<td>$15,000</td>
</tr>
<tr>
<td>Wilmington Trust</td>
<td>$15,000</td>
</tr>
<tr>
<td>Ann Wilson</td>
<td>$15,000</td>
</tr>
<tr>
<td>Andrew Wilson</td>
<td>$15,000</td>
</tr>
<tr>
<td>Winnibro Petroleum Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Winwood Children’s Center</td>
<td>$15,000</td>
</tr>
<tr>
<td>Nancy Wolfe Lane</td>
<td>$15,000</td>
</tr>
<tr>
<td>Glen Wolther and Donna Rosen</td>
<td>$15,000</td>
</tr>
<tr>
<td>Wembley Bond Dickinson</td>
<td>$15,000</td>
</tr>
<tr>
<td>Woody Woodall</td>
<td>$15,000</td>
</tr>
<tr>
<td>Woodforest National Bank</td>
<td>$15,000</td>
</tr>
<tr>
<td>Jerry Wordsworth</td>
<td>$15,000</td>
</tr>
<tr>
<td>World Bank Group Community Outreach Program</td>
<td>$15,000</td>
</tr>
<tr>
<td>World Travel Holdings</td>
<td>$15,000</td>
</tr>
<tr>
<td>World Wide Technology, Inc.</td>
<td>$15,000</td>
</tr>
<tr>
<td>John Wright</td>
<td>$15,000</td>
</tr>
<tr>
<td>Howard Yang</td>
<td>$15,000</td>
</tr>
<tr>
<td>Yokohama Tire Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Yoslov Family Foundation</td>
<td>$15,000</td>
</tr>
<tr>
<td>Young Conaway Stargatt &amp; Taylor, LLP</td>
<td>$15,000</td>
</tr>
<tr>
<td>Sherry Zander</td>
<td>$15,000</td>
</tr>
<tr>
<td>Cathy and Scott Zeilinger</td>
<td>$15,000</td>
</tr>
<tr>
<td>The Zenith Insurance Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Zinkin Family</td>
<td>$15,000</td>
</tr>
<tr>
<td>Zotec Partners, LLC</td>
<td>$15,000</td>
</tr>
<tr>
<td>Zurich American Insurance Company</td>
<td>$15,000</td>
</tr>
<tr>
<td>Joseph Zvesper</td>
<td>$15,000</td>
</tr>
<tr>
<td>Zyedge</td>
<td>$15,000</td>
</tr>
<tr>
<td>Anonymous in Honor of Diane Anonymous (9 donors)</td>
<td>$15,000</td>
</tr>
<tr>
<td>Top Campaign Fundraisers</td>
<td>#NoMoreNames</td>
</tr>
</tbody>
</table>
Lynn Aronberg  
Ashley Haver’s Campaign Team  
Daniel Atamanchuk  
Sherrie Austin  
Paige Babbs  
Richard Babineau  
Phyllis Bailey Brooks  
Beau Baker  
Kelly Baker  
Ginger Baldwin  
Brad Ball  
Claudia Ballas Latch  
Trae Ballinger  
Amanda Baltz  
Bank of America  
Bank of America / Merrill Lynch  
Naader Banki and Team Iron Banki  
Barclays  
Jessica Barnett  
Lauren Barr Jebsen  
Sarah Barwell  
Battle Brenna  
Louisa Bayburtian  
Bears Against Blood Cancer  
Erin Beasley  
Jeri Ann Beckworth  
Holden Beecher  
Rasha Beg  
Joanna Belt  
Ben Clinkenbeard’s Campaign Team  
Ben Fogel’s Campaign Team  
Ben Gerber’s Campaign Team  
Lynn Bennink  
Pete Benoist  
Jesse Bergland  
Chris Berlow  
Reid Besch  
Darren Betters  
Michael Blackman  
Blackstone  
Laura Blanchard, PA-C  
Hudson Blass  
Charles Blocksdidge  
Bloomberg Marathon  
Bloomberg Spring Team  
BMC  
BMC Triangle Market and Corporate Support  
Emilia Boggs  
Beau Bokelman  
Dr. Uma Borate and Team OHSU  
Scott Bores  
Boston Creates Hope  
Boston Reunion Team  
Rod Bowe  
Bowe’s Blood Brigade  
Blair Bowen  
Brad Stinson’s Campaign Team  
Lily Brady  
Gayle Brand  
Madison Breazeale  
Jenn Bringle  
Preston Browder  
Jarad Brown  
Jennifer Brown  
Kim Brown  
Tami Brown  
Bryan Jansen’s Campaign Team  
Bryce Unger’s Campaign Team  
Bulldogs Bite Cancer  
Joe Bunce  
Jessica Burgess  
Burlington Stores Corporate Office  
Julie Buschman  
Lucy Byer  
Avery Byrne  
John Calys  
Camille Miura’s Campaign Team  
Camille Olivere’s Campaign Team  
Dee Campbell  
Cancer Crusaders  
Cancer Crushers  
Cancer is Wack - Blake Kelly,  
Christian Kelly, and Justin Emi  
Cancers Answer  
Mark B. Candelaria  
Robert “Spider” Cantley  
Can’t Stop the Healing  
Cardinals Cure Cancer  
Jim Carman  
Carmen Harris’s Campaign Team  
Bill Carteaux  
Carter’s  
CBH Homes  
Cetera Financial Group - Friends of  
Luanne Graham  
Champions For A Cure  
Charles Esten’s Team Addie  
Nischal Chennuru  
Sahm Cho  
Chris Townsend’s Campaign Team  
James Chrisman  
Gabrielle Christie and Team Bring The Change  
Christine Clawson’s Campaign Team  
Joe Ciccarelli  
Circle of Hope Campaign Team  
Esther Cirelli  
Sarah Cirelli and Team Bad Blood  
City of San Antonio  
Christine Clawson  
Ben Clinkenbeard  
Jamie Cobb  
Adam Cohan  
Ryan Cohen  
Meredith Coleman  
Colton’s Army  
Compass Self-Storage, LLC  
Ava Connell  
Connell High School  
Peter Connolly  
Constance Howlett’s Campaign Team  
Kelly Cook  
Gordon Cooke  
Josh Cooper  
Ken Corbett  
Corts Girls Curing Cancer  
Catherine Covell  
Chris Coxon  
Leslie Coxon  
Bill Craighead  
Sera Cremona  
Jenny Crow  
Crusaders for a Cure  
Crusaders for a Cure  
Joe Cupoli and Team Operation Hope  
Cure Cancer Crusaders  
Cure Collective  
Daniel Dagit, Jr.  
Lindsey Dameshghi  
Lyndsey Danberry  
Dani Frisch Harkin’s Campaign Team  
Daniel Atamanchuk’s Campaign Team  
Daniel Sullivan’s Campaign Team  
Dara Spearman’s Campaign Team  
Darren Betters’s Campaign Team  
David Arkooosh’s Team  
Lisa Davis  
Schauqi De Young  
Mario DeFrancesco III  
Daniel DeGuire  
Delbarton School  
Demetrious Puente’s Campaign Team  
Derek Miller’s Campaign Team  
Joseph DeSabia  
Yash Desai  
Eric Dewey  
Katherine DelWulf  
Discount Tire  
Bygie Dixon  
Dominic Tully’s Campaign Team  
Karissa Dominick  
Belia Doro and Cheering for a Cure  
The Dream Team  
Roya Ebrahimi-Qajar  
Martin Einhorn  
Eric Eissensatat  
Elizabeth Greever’s Campaign Team  
Richard Ellin  
Maya Ellison  
Eric Dewey’s Campaign Team  
Eric Grossman’s Campaign Team  
Erika Pizeck’s Campaign Team  
Erika Salinas’s Campaign Team  
Grayson Ertel  
Lauren Esposito  
Ethan & Sidney’s Campaign Team  
Lilly Evans  
Everett Fire Department  
FAMILY  
Gary Farmer  
Katherine Farmer-Thornhill  
Jonathan Faust  
Sofia Fernandez  
Ed Ferrell  
Jack Ferruzzo  
PIS  
John Fitch  
Waring Fleitas  
Florida Power & Light  
Ryan Floyd  
FoCo Cure  
Ben Fogel  
Megan Freas  
Erin Freeman  
Freshman Knights  
Delisi Friday  
Friends for a Cure  
Dani Frisch Harkin  
Bridge Fry  
Taylor Fry  
Mina Garavi  
Lily Gardiner  
Virginia Garner  
Michelle Gaulding
Hendry’s Heroes  
Charlotte Henry  
Herb’s Chain Gang Powered by Karlie’s Krew  
Hikers4Life  
Delaney Hill  
Rachel Hines  
Caleb Hinson  
Thomas P. Hogerty and Team Blood Brother  
Hoden Beecher’s Campaign Team  
Eli Holder  
Eva Hooten  
Robert Hope  
Hopeful Hearts  
Tim Houterloot  
Kelli Howard  
Tracy Howard  
The Howard Hughes Corporation  
Constance Howlett  
John Huber  
Katy Huie Harrison  
Morgan Hunt  
Jonathan Hutton  
Lindsay Iadeluca  
Clayton Idle  
Renjitha Ignatius  
In honor of all who have battled Hodgkin’s Lymphoma (Chris Saizan)  
In honor of Bill Fores (Team 209)  
In honor of Caleb McNitt (Ride For Dads)  
In honor of Cassidy Sidhu and in Memory of Lou Cole (Thea Campbell)  
In honor of Firas Nassif (Taro Arai, Mikuni Charitable Organization)  
In honor of Frank Amaral (Team 209)  
In honor of Garrett Heisinger (Team Cureageous)  
In honor of Lisa Villamil (Team Living Victoriously)  
In honor of Mike Tooley (Team Tooley)  
In honor of Omar Ali (Abdul Ali)  
In honor of Ryan Tooley (Team Tooley)  
In honor of Team Don’t Stop Believing (Firas Nassif)  
In memory of Bernice N. Zahn (Melvin Bradley)  
In memory of Dennis Bravo (Team 209)  
In memory of Irene Christopulos and Donald Procida (Marisa Christopulos)  
In memory of Joe Fitzgerald (Kate Fitzgerald)  
In memory of Rami Zakhour (Firas Nassif)  
Joe Innacone  
InvinciBill  
Jack Maine’s Campaign Team  
Trent Jackson  
Ava Jambor and Noah’s Army  
Denisse James  
Janine Ward’s Campaign Team  
Bryan Jansen  
Jason Smith’s Campaign Team  
Jeffrey Rotner’s Campaign Team  
Jen Thomas’ Campaign Team  
Jennifer Brown’s Campaign Team  
Jeremy Schwibner’s Campaign Team  
Jeni 4 a Cure  
Jan Jernigan  
Jessica Burgess’ Campaign Team  
Jessica Henderson - Funiestas’ Campaign Team  
Jhansi Koduri’s Campaign Team  
Jil Makzman’s Campaign Team  
Wendy Jirsa  
Joe Maio’s Campaign Team  
John Huber’s Campaign Team  
John McDonough’s Campaign Team  
Jhonny Mercado’s Campaign Team  
Nora Johnsmyer  
Andrea Johnson  
Bert Johnson  
Tracy Johnson  
Andrew Jones and Team Live  
Life Stronger  
Chris Jones  
Lauren Jones  
Jonesin’ for the Cure  
Julie Buschman’s Campaign Team  
Julie McPherson’s Campaign Team  
Just Cure It – CTWHV  
Just Cure It – Illinois  
Just Cure It – NYC  
Just Cure It! – Long Island  
Just Cure It! – PHX  
Just Peachy  
Lilly Kannapel  
Katherine Thornhill’s Campaign Team  
Kathy Pidgeon’s Campaign Team  
John Katsetos  
Michael Katsock  
Peter Katz  
Jim Kaufman  
Micaela Keane  
Keane on Beating Cancer  
Ken Schwing’s Campaign Team  
Jennifer Kennedy  
Brett Kessler  
Eric Kesti  
Amen Khadiwala  
Aamilah Khanu  
Kick Leukemia’s Zaas  
Kate Kilroy  
Parker Knk  
Chuck Kiven  
Kiven, Kotler, Lieberman, Fox, Goldschmidt, Kepes & Lev  
Lance Knez  
Knockout Blood Cancer  
Jhansi Koduri, M.D.  
Stanley Koehl  
Matthew Koff  
Poppers  
Lee Korn  
Bob and Jenny Kottler  
KPMG Cycle  
Kristen Krikorian  
Kristen Meyer’s Campaign Team  
Kristie Welte’s Campaign Team  
Dave Kuba and Team Reality Fights  
Jessica Kubat  
Michelle Kuhn  
J. Marc Kurowski  
Max Landwith  
Lanphere Auto Group  
Blair Larkins-Seyfried  
Larry Treen Jr.’s Campaign Team  
Lauren Esposito’s Campaign Team  
Lauren Rigg’s Campaign Team  
Lauren Simone’s Campaign Team  
Emily LeBlanc  
Katherine Lee  
Dr. N. Ray Lee  
Chad Lefers  
Lehigh Valley Circle of Hope  
Elizabeth Lehr  
Leslie Coxon’s Campaign Team  
Tyler H. Lester  
Alanna Levine  
Alexa Levine  
Valerie Lewis
Kari Souers  
Jonathan Spaeth  
Dara Spearman  
Allyson Spring  
Troy Springer and Cinzia Rolling  
Stacie Sheely’s Campaign Team  
Stacy Goldstein’s Campaign Team  
Nathan Stallings  
Dean Stamoulis  
Stanley Koehl’s Campaign Team  
Nick Starr  
Stater Bros. Markets  
Kevin Steckley  
Donald and Margaret Steiner  
Sullie Stephens  
Kate Stevens  
Anna Stewart  
Brad Stinson  
Raul Storey-Rojas  
Justin Stout  
Abigail Stoy  
Stratford School at Osgood  
Dean Stamoulis  
Sauer Strong  
Heather Stubblefield  
Daniel Sullivan  
Katie Sullivan Taulane  
Vonnie Sullivan  
Summer Hall’s Campaign Team  
Susan Rheingold’s Campaign Team  
Stephen Strickland  
Team Cure-aLLS  
Team Deconstructing Cancer  
Team DeFREEZING Cancer  
Team D.R.E.A.M  
Team Droplet Like It’s Hot  
Team Fearless Dragons  
Team Fight Cancer  
Team Fire Hearts  
Team Go Gold  
Team Gordo’s Groupies  
Team Hamlin’s Cure-saders  
Team Heart Roots  
Team Hero - Luke Hatfield  
Team Ho’omau  
Team Hope  
Team Hudson  
Team Husky  
Team Hutton 1045  
Team Jim Thorpe  
Team JumpingForJoy  
Team Justin  
Team Leticia Juarez in Memory of Pamela Johnston  
Team Live Love and Adventure - Patty Leehmuis  
Team Lori  
Team Lymph-busters  
Team Maddie’s Mission  
Team Mighty  
Team NARS  
Team Nike  
Team Panthers Against Cancer  
Team Phoenix  
Team PrC: Run for Richard  
Team Reid  
Team Scream Survivor  
Team Soulunination  
Team Stanley  
TEAM SURVIVOR  
Team Teeny for the Cure  
Team Tobon  
Team Turn Up For The Cure  
Team Victory Royale  
Team Ward Law Group  
Team Wendy’s  
Team Wishes for a Cure - Heather Hibbard  
Team Wishful Workers - Jennifer Oz  
Team Worth the Fight  
Team Zephyr  
Terumo BCT  
The Three MuskeCUREs  
The Tiger Stripes  
Nichoie Theriault  
Andy Thieman  
Kate Thomas  
Kennedy Thomason  
Robin Thurau  
Tim Houterloot’s Campaign Team  
TNT Caballeros  
Toequville Asset Management  
Megan Toner  
Grace Toomey  
Brianna Torgerson  
Tour 2 Cure  
Cara Tovissi  
Matt Tovrog  
Chris Townsend  
Tracy Johnson’s Campaign Team  
Lary W. Treen Jr  
Yvette Tremonti  
Trent Jackson’s Campaign Team  
Annie Trimberger  
Trvidia Health, Inc.  
Dominic Tully  
Turkey Shoot Golf Tournament  
Twiggy’s Dream Team  
Bryce Unger  
Grace Unger  
Sohan Upadhya  
Lauren Valentine  
Valerie Lewis’s Campaign Team  
VALiant Warriors  
Brent VanLoo  
Nicholas Van Zandt  
Julia Vasco  
Mr. and Mrs. Leo Vecellio  
Carmen Vega  
Anthony Velardi  
Zarmeena Vendal, MD  
Banner Vicary  
Victoria Santos’s Campaign Team  
Jenny Vipperman  
Nick Vizzoza  
Vystar Credit Union  
Devon Wagner  
Walgreens  
Mike Wall  
Patrick Wall  
Amy Waliner  
Gregory Ward  
Janine Ward  
Lindsey Ward  
Wayne Warrington  
Warriors 4 LLS  
Washington Gas - 10th Annual Golf Tournament  
Katie Waters  
Watertown Middle School  
The Wawa Foundation  
Weddington Middle School  
Weiler Foundation  
Greg Weimer  
Kristie Welte  
West Ridge Middle School  
Whaboob  
When Pigs Fly: Making the Impossible Possible  
Jenna Whitehead  
Nancy Whitman  
Jessie Wiener  
Wilkes & McHugh  
Will Rigby’s Campaign Team  
Will Rogers’s Campaign Team  
William Mason High School  
Rob Williams  
Dwayne Wilson  
JP Witkop  
Wolfpack (Hunting For A Cure)  
Stephanie Wong  
World of Warriors  
Jillian Wright  
Randy Writz  
Manuela Yanez  
Preston York  
Matthew Yost  
Yvette Tremonti’s Campaign Team  
Jade Zaas  
Hala Ziad  
Claire Ziegler  
Bella Zinkin and Sienna Saxton
Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Edward Darden Baines*
Michelle Bargeron*
Alice Ann Bien*
Joyce Boice*
Margaret and John Bruner*
William P. Caloccia*
Kalpana Chakraburty in memory of Shib Chakrabarty
Roseann Comstock*
Alan Cook*
Gregory D’Angelo in memory of Diane D’Angelo
Robert DeVolder*
Nicholas Dissler*
Peggy and Margaret Dupaquier*
Robert Elms*
Judith Erickson*
Anita Foster*
Grace Fram*
Barbara Frattura* in memory of Pasquale (Pat) R. Frattura
Nancy Hall*
Victoria Harris*
Ferris Hartman*
Susanne Hassell*
Alice Hejl*
Barbara Hellman*
Rowena Huddle*
Lewis Kaplan*
George Keleher*
John Kellenyi**
Wayne Kenfield*
James Kimble*
Else Korb*
Legion Kramer*
Martha Lacy in memory of William R. Lacy
Albert Lee
Sanford Levinson in memory of Elaine Levinson
Howard Bruce Linden in memory of Walter William Linden
Debra Linick
Margaret MacMurray*
Ronald Marony*
Elaine Meyers-Matloff*
Emily Papapietro*
Mary Alice Parks*
Mary Perluss*
Renee Pittin*
Gretchen Pressburg
Eugene Regener, III*
Michael Rinaldi*
Gene Rochlin*
Sally Rossster*
Gail Secrist*
Bruno and Irma Selmi*
Roselle Shaw*
DJ Smith-Brooks*
Robert Snincak*
Wanda Starkey*
Jo Ann Taylor*
Mitchell Tobin and Susan Jacobson in memory of Nancy Tobin
Elizabeth Duffy Traynham*
Robert Trusler*
Peter Vlahakos*
Alice Wambach*
Abie Werth*
Thomas West*
Harvey White*
Mark Wiener*
John Wilhelm*
Catherine Woodfield*
Shirley and Hal Wright*
Muriel Yuster*
Anonymous (6)
* Deceased
† We proudly recognize John Kellenyi, generous, longtime supporter and Beat AML Campaign co-chair, for his leadership, compassion, and commitment

Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation -Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund
Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund
The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The United Food and Commercial Workers (Canada) Endowment Fund
The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund
Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.


Patient Support & Public Policy Portfolio is funded in part by Allegheny Foundation, The John and Frances Beck Family Foundation, UCLA Kaiser Permanente Center of Health Equity, and anonymous.


Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Lisa Norcia Cheskin and Barry Cheskin and the Eric Scherbarth Leukemia Research Foundation, Inc.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Alex Boggs, Steven and Sandy Brannon, and Sharon and Paul Dillon.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Leslie and Larry Nance.

Hodgkin Lymphoma Research Portfolio is funded in part by AM Charity Fund and Terry D. and Carol A. Agness Charitable Trust.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by John and Nonnie Barbey, Lisa Norcia Cheskin and Barry Cheskin, Cristina and Timothy Lindenfelsier, Robert and Nancy Rosen, Lois and Jerry Rosenblum, and Michael L. Smith.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Donna Hartman, and Rochelle Klutch.

Immunotherapy Portfolio is funded in part by The Alice Lawrence Foundation, Inc. and Janet Faulkner.

Information Resource Center (IRC) is funded in part by Adel Barry.

Lymphoma Diagnostics Program is funded in part by Chiyoko Furukawa.

Therapy Acceleration Program is funded in part by Robert and Nancy Rosen, Lois and Jerry Rosenblum, and Allen Zachary.

The Susan Lang Pay-It-Forward Transportation Assistance Program is funded in part by The Grainger Foundation, Lang / Stiglitz Family Fund, and anonymous.


Precision Medicine Initiative is funded in part by The Harry T. Mangurian Jr. Foundation, Inc.
Leadership

National Board
Volunteers serve on our National Board of Directors providing leadership and governance to help find blood cancer cures.

Officers

Chairman of the Board
Jorge Benitez
Fort Lauderdale, FL

Vice Chair
Bart Sichel
Bucks County, NJ

Secretary/Treasurer
Ralph E. Lawson, FHFMA, CPA
Parkland, FL

At Large
Kathleen Meriwether
Ernst & Young, LLP
Philadelphia, PA

Directors

William G. Behnke
The Behnke Group
San Antonio, TX

Peter Brock
Brock Development
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Renzo Canetta, MD
Madison, CT

Casey Cunningham, MD.
Sante Ventures
Houston, TX

William S. Dalton, MD, PhD
2Gen
Tampa, FL

Samuel Ebers, III
Chapel Hill, NC

Christopher Flowers, MD
Emory University
Atlanta, GA

Janice Gabrilove, MD.
Icahn School of Medicine at Mt. Sinai
New York, NY

Bernard H. Garil
Delray Beach, FL

John Greene
Salesforce
San Francisco, CA

Francie Heller
Arabesque Asset Management
New York, NY

Michelle LeBeau, PhD
University of Chicago
Comprehensive Cancer Center
Chicago, IL

Connie L. Lindsey
Northern Trust
Chicago, IL

Ruben Mesa, MD
Mays Cancer Center
San Antonio, TX

Ted Moroz
The Beer Store Ontario
Toronto, ON, Canada

Harry Moseley
Zoom
San Jose, CA

Lynne O’Brien
McLean, VA

Maria Persky, JD
WOMN LLC
Ridgefield, CT

Donald Proctor
Bk97 Digital
Walnut Creek, CA

Robert Rosen
Greyhawk Capital Advisors LLC
West Palm Beach, FL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Jeff Sachs
Jones Lang LaSalle
Duluth, GA

Kenneth Schwartz
Ernst & Young, LLP
New York, NY

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & Chief Executive Officer

Danielle Gee
Chief of Staff

Kathy Griesenbeck
Executive Vice President
Chief Relationship Officer

Marcie Klein
Executive Vice President
Chief Communications Officer

Margo Lucero
Executive Vice President
Corporate Partnerships and Development

JR Miller
Executive Vice President
Chief Financial Officer

Gwen Nichols, MD
Executive Vice President
Chief Medical Officer

Tom Osgood
Executive Vice President
Chief Human Resources Officer

Coker Powell
Executive Vice President
Products & Campaign Development

Vanessa White
Executive Vice President
Chief Development Officer

The Leukemia & Lymphoma Society of Canada

Alicia Talarico
President
Canadian Operations

Offices

United States:
thttps://www.lls.org/chapter-selection-page

Canada:
http://www.llscanada.org/chapter-selection-page
The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.